P2 - Poster Session II

Event Time:	Monday April 23, 2018 11:30 am to 7:00 pm
Topic(s):	Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-ophthalmology/Neuro-otology, Pain and Palliative Care, Research Methodology, Education, and History
Director(s):
Description:	A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 p.m. to 7:00 p.m.
Completion Message:
CME Credits:	0
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
11:45 AM - 11:50 AM	P2.027	Faculty
11:50 AM - 11:55 AM	P2.028	Faculty
11:55 AM - 12:00 PM	P2.029	Faculty
12:00 PM - 12:05 PM	P2.030	Faculty
12:05 PM - 12:10 PM	P2.031	Faculty
12:10 PM - 12:15 PM	P2.032	Faculty
12:15 PM - 12:20 PM	P2.033	Faculty
12:20 PM - 12:25 PM	P2.034	Faculty
12:25 PM - 12:30 PM	P2.035	Faculty
12:30 PM - 12:35 PM	P2.036	Faculty
5:30 PM - 7:00 PM	Poster Author Standby Time	Faculty

Disclosures
Speaker	Disclosure

Abstract Presenters
Undergraduate Medical Education: Assessment and Curricular Design I
Start Time	Pub.	Title	Presenter
5:30 PM	001	Common difficulties medical students have with the neurological physical exam are identified by direct observation.	Juliana Coleman, MD Disclosure: Dr. Coleman has nothing to disclose.
5:30 PM	002	Evaluation of a Single Year Competency-Based Clerkship Alternative to Effectively Navigate a Fourth-Year to Third Year Curricular Transition	Jeff Kraakevik, MD Disclosure: Dr. Kraakevik has nothing to disclose.
5:30 PM	003	Developing a Student-Centric/Student Responsive Four Week Neurology Clerkship	Raghav Govindarajan, MD, FAAN Disclosure: Dr. Govindarajan has nothing to disclose.
5:30 PM	004	Published Headache OSCEs Have Excellent Inter-rater Reliability	Maryam Shakir, MPH Disclosure: Dr. Shakir has nothing to disclose.
5:30 PM	005	Why aren't you giving feedback?	Doris Kung, DO Disclosure: Dr. Kung has nothing to disclose.
Undergraduate Medical Education: Novel Formats
Start Time	Pub.	Title	Presenter
5:30 PM	006	Movement Disorders Video Curriculum for Neurology Clerkships and Residency Programs	Sagari Bette, MD Disclosure: Dr. Bette has nothing to disclose.
5:30 PM	007	Assessment Of The Difficult Components Of Neurological Exam Performance In Medical Students	Yi Li, MD Disclosure: Dr. Li has nothing to disclose.
5:30 PM	008	Animated Neurological Exam Videos in PBL Cases	J. Douglas Miles, MD, PhD Disclosure: Dr. Miles has nothing to disclose.
5:30 PM	009	Student Neurology Clerkship Improvement Project ("SNIP")	Victoria Cannon, MD Disclosure: Dr. Cannon has nothing to disclose.
5:30 PM	010	Incorporating Formal Nutrition Education into a Medical School Curriculum: A Student-Initiated Lecture Series	Vanessa Baute, MD Disclosure: Dr. Baute has nothing to disclose.
5:30 PM	011	Expert Patient Tutors: The Eradication of Neurophobia	Gina Hadley, MD Disclosure: Dr. Hadley has nothing to disclose.
Health Services Research and Methodologies
Start Time	Pub.	Title	Presenter
5:30 PM	012	Common Data Elements (CDEs) for Biomechanical Devices used in Blunt Head Impact and Blast Exposure Dynamics: The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Department of Defense (DOD) Version 1.0 Recommendations	Kristen Joseph, MA Disclosure: Dr. Joseph has nothing to disclose.
5:30 PM	013	Development of diagnostic criteria to facilitate research in mitochondrial disorders: a proposal from the North American Mitochondrial Disease Consortium.	Valentina Emmanuele, MD Disclosure: Dr. Emmanuele has nothing to disclose.
5:30 PM	014	Streamlining Clinical Research in Sports-Related Concussion: The National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH), and Department of Defense (DOD) Sport-Related Concussion Common Data Elements (CDEs)	Kristen Joseph, MA Disclosure: Dr. Joseph has nothing to disclose.
5:30 PM	015	Registration status of clinical trials published in core neurology journals: a cross-sectional study	Jose Merino, MD, MPhil, FAAN Disclosure: Dr. Merino has received personal compensation in an editorial capacity for the BMJ as a research editor.
5:30 PM	016	A Common Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and Centers for Disease Control and Prevention (CDC) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Common Data Elements (CDEs)	Robin Feldman Disclosure: Dr. Feldman has nothing to disclose.
Education: Career Choice and Attitudes
Start Time	Pub.	Title	Presenter
5:30 PM	017	Headache interest in US academic neurology leadership: a cross-sectional study	Matthew Robbins, MD, FAAN Disclosure: Dr. Robbins has received personal compensation in an editorial capacity for Springer (Current Pain and Headache Reports). Dr. Robbins has received research support from eNeura (clinical trial; funds to institution).
5:30 PM	018	Neurology Residency Websites: A Critical Evaluation.	Adeel Memon Disclosure: Dr. Memon has nothing to disclose.
5:30 PM	019	The Rutgers-NJMS Experience: Why Are Our Medical Students Increasingly Applying to Adult Neurology?	Jessy Walia, MBBS Disclosure: Dr. Walia has nothing to disclose.
5:30 PM	020	Changing the Image of Neurology	Yolanda Reyes-Iglesias, MD Disclosure: Dr. Reyes-Iglesias has nothing to disclose.
5:30 PM	021	The Importance of Neurology as a Required Third-Year Clerkship: a Medical Student Survey	Enmanuel Perez Disclosure: Dr. Perez has nothing to disclose.
5:30 PM	022	The Impact of Early Medical School Exposure to Clinical Neurology on Career Interest in Neurology	Yasmin Aghajan Disclosure: Dr. Aghajan has nothing to disclose.
5:30 PM	023	NA	NA NA Disclosure:
5:30 PM	024	NA	NA NA Disclosure:
5:30 PM	025	NA	NA NA Disclosure:
5:30 PM	026	NA	NA NA Disclosure:
Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session
Start Time	Pub.	Title	Presenter
5:30 PM	027	Machine-learning in neurodegeneration: evaluation, optimisation and validation of MRI-based diagnostic methods	Peter Bede, MD Disclosure: Dr. Bede has nothing to disclose.
5:30 PM	028	Skeletal Muscle Interstitial Amyloid in Anoctaminopathy-5: Does it Matter?	Charenya Anandan, MD Disclosure: Dr. Anandan has nothing to disclose.
5:30 PM	029	Egr2-dependent microRNA-138 is Dispensable for Peripheral Nerve Myelination	Hsin-Pin Lin Disclosure: Dr. Lin has nothing to disclose.
5:30 PM	030	The Long Exercise Test in Primary Periodic Paralysis: a Bayesian Analysis	Daniel Simmons, MD Disclosure: Dr. Simmons has nothing to disclose.
5:30 PM	031	Congenital Myasthenic Syndromes (CMS) Due to Impaired Principal Coupling Pathway in the ? Subunit of Muscle Acetylcholine Receptor (AChR)	Xin-Ming Shen, PhD Disclosure: Dr. Shen has nothing to disclose.
5:30 PM	032	Integrated MRI and [11C]-PBR28 PET Imaging to Characterize In vivo Glial Activation in Amyotrophic and Primary Lateral Sclerosis: Cross Sectional and Longitudinal Study	Mohamad Alshikho Disclosure: Dr. Alshikho has nothing to disclose.
5:30 PM	033	Undiagnosed Congenital Myasthenic Syndromes in Adult Neuromuscular Practice: a Long Road to Diagnosis and Treatment.	Justin Kao, MBChB Disclosure: Dr. Kao has nothing to disclose.
5:30 PM	034	ALS progression over short time intervals: early insights from the ongoing ALS-at-home study	Seward Rutkove, MD Disclosure: Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, and Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc.. Dr. Rutkove holds stock and/or stock options in Myolex, Inc.. Dr. Rutkove has received research support from Flex-Pharma, Inc..
5:30 PM	035	Efficacy of Dichlorphenamide in Primary Periodic Paralysis: Pooled-Data Analysis of Two Phase 3 Clinical Trials	Perry Shieh, MD, PhD Disclosure: Dr. Shieh has nothing to disclose.
5:30 PM	036	Decreased EEG Spectral Power and Increased Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Amyotrophic Lateral Sclerosis	Stefan Dukic Disclosure: Dr. Dukic has nothing to disclose.
Parkinson's Disease: Therapeutics
Start Time	Pub.	Title	Presenter
5:30 PM	037	Effects of Probiotics on Constipation, Neurological Symptoms, and Quality of Life Associated with Parkinson's Disease	Duarte Machado, MD Disclosure: Dr. Machado has nothing to disclose.
5:30 PM	038	Exploratory risk analysis for motor complications and non-motor symptoms: observations in a registry of a tertiary Parkinson's disease center in Brasilia, Brazil	Talyta Grippe, MD Disclosure: Dr. Grippe has nothing to disclose.
5:30 PM	039	A Phase 2 study of Isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): Baseline characteristics and study update	Tanya Simuni, MD Disclosure: Dr. Simuni has nothing to disclose.
5:30 PM	040	Optimizing Delivery of Carbidopa/Levodopa via the Accordion Pill™: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers	Nadav Navon Disclosure: Dr. Navon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Intec LTD Jerusalem.
5:30 PM	041	Objective Evaluation of Levodopa Response on Gait and Balance	Alexandra Fowler Disclosure: Dr. Fowler has nothing to disclose.
5:30 PM	042	Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS in PPMI study	Zhen Xiao, PhD Disclosure: Dr. Xiao has nothing to disclose.
5:30 PM	043	Pharmacokinetics of ADS-5102 (amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia	Robert Hauser, MD, MBA, FAAN Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities. Dr. Hauser reports receiving licensing fee payments from the University of South Florida. Dr. Hauser has received research support from Abbvie Pharmaceutical Research and Development, Astra Zeneca, Axovant, Biotie Therapies, Acorda/Civitas Therapeutics, Inc, Axovant, Biogen, Biotie, Enterin, Cynapsus/Sunovion, Intec, Impax Pharmaceuticals, Kyowa Kirin Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Neuroderm, Pfizer, PPMI (MJFF), and Hoffman - La Roche.
5:30 PM	044	The iNDiGO study: A multicenter, randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD	Karl Kieburtz, MD, FAAN Disclosure: Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with the National Institutes of Health, the Michael J. Fox Foundation, Medivation, Neurosearch, the United States Food and Drug Administration, Veterans Administration, AbbVie, and Acorda.
5:30 PM	045	A Phase 3 Study of Tozadenant (TOZ-PD) as a Maintenance Therapy for Patients With Parkinson's Disease Experiencing Motor Fluctuations: Characterization of Study Population	Karl Kieburtz Disclosure: Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with the National Institutes of Health, the Michael J. Fox Foundation, Medivation, Neurosearch, the United States Food and Drug Administration, Veterans Administration, AbbVie, and Acorda.
5:30 PM	046	Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson's Disease	James Boyd, MD Disclosure: Dr. Boyd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Teva, Lundbeck, Chrono Therapeutics, Neurocrine and Medical Education Resources. Dr. Boyd has received research support from Michael J. Fox Foundation, NIH/NINDS, Auspex, Biotie, CHDI Foundation, NeuroDerm, Chrono Therapeutics, Vaccinex, AbbVie Inc.
5:30 PM	047	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease Patients Receiving ≥ 2000 mg Daily Dose of Levodopa	Cindy Zadikoff, MD Disclosure: Dr. Zadikoff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, USworldMeds, Acadia, UCB, St Jude, Merz, Teva, and Lundbeck. Dr. Zadikoff holds stock and/or stock options in Dial N Doc. Dr. Zadikoff has received research support from AbbVie, Allergan, St Jude for unrestricted educational grants.
5:30 PM	048	Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson's Disease - INSIGHTS Study	K. Ray Chaudhuri Disclosure: Dr. Chaudhuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Voyager Therapeutics, and Serina Therapeutics. Dr. Chaudhuri has received research support from AbbVie Inc.
Parkinson's Disease: Phenomenology, Epidemiology and Rating Scales
Start Time	Pub.	Title	Presenter
5:30 PM	049	Dry facts are not always inviting: an analysis of Korean videos about Parkinson's disease on YouTube	Beomseok Jeon, MD Disclosure: Dr. Jeon has nothing to disclose.
5:30 PM	050	Clinical factors associated with clinician certainty in diagnosis of idiopathic Parkinson's disease	Kishan Ughreja, BA Disclosure: Dr. Ughreja has nothing to disclose.
5:30 PM	051	Item Response Theory Analysis of the Unified Dyskinesia Rating Scale Items	Christopher Goetz, MD, FAAN Disclosure: Dr. Goetz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific, the International Parkinson and Movement Disorder Society, Cray-Huber Attorneys and the University of Pittsburgh. Dr. Goetz is employed by Rush University Medical Center. Dr. Goetz has received (royalty or license fee or contractual rights) payments from Elsevier Publishers, Oxford University Press and Wolters Kluwer. Dr. Goetz has received research support from NIH, the Michael J. Fox Foundation, the Parkinson's Disease Foundation and the International Parkinson and Movement Disorder Society (IPMDS).
5:30 PM	052	A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson's Disease (PD) Patients with Dyskinesia	Rajesh Pahwa, MD, FAAN Disclosure: Dr. Pahwa has received consulting fees from Abbvie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience, and US World Meds. Dr. Pahwa has received personal compensation in an editorial capacity as the Co-Editor-In-Chief of the International Journal of Neuroscience. Dr. Pahwa has received research support from Abbvie, Adamas, Avid, Biotie, Boston Scientific, Cala Health, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, and Pfizer.
5:30 PM	053	Smoking and Coffee Consumption Preceding Clinically-diagnosed Synucleinopathies: A Case-control Study in Olmsted County MN (1991-2005).	Jinna Yu Disclosure: Dr. Yu has nothing to disclose.
5:30 PM	054	Predictors of Disability in Parkinson Disease: Motor vs. Cognitive Impairment Using MMSE vs. MoCA	Allison Snyder, MD Disclosure: Dr. Snyder has nothing to disclose.
5:30 PM	055	Communication Regarding Off Time with People with Parkinsons and their Caregivers: Qualitative Analysis of Physician Interviews	Tara Rastgardani, MD Disclosure: Dr. Rastgardani has nothing to disclose.
5:30 PM	056	Foundations for a Patient-Reported Natural History of Parkinson Disease: Cross-sectional Analysis of the MJFF Fox Insight (FI) Platform	Lakshmi Arbatti Disclosure: Dr. Arbatti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grey Matter Technologies.
5:30 PM	057	Stumbling, Near-falls, Freezing or Postural Instability: What Predicts Falling Best in Parkinson Disease?	Zahra Nooshin Rezvani Disclosure: Dr. Rezvani has nothing to disclose.
5:30 PM	058	Diagnostic Impact of Movement Disorders Subspecialty Consultations at a VA Hospital	Brandon Barton, MD Disclosure: Dr. Barton has nothing to disclose.
5:30 PM	059	Levodopa-induced dyskinesias in Parkinson disease: a population based-cohort study in Olmsted County, MN (1991-2010)	Pierpaolo Turcano, MD Disclosure: Dr. Turcano has nothing to disclose.
5:30 PM	060	A Real-World Inquiry of the So-Called Parkinsonian Personality -- Comparing No-Show Rates of the Neurology Outpatients with and without Parkinson's disease (PD)	Jeremiah Bell, MD Disclosure: Dr. Bell has nothing to disclose.
5:30 PM	061	Parkinson's Diagnostic Accuracy- What diagnoses cause the most diagnostic-switches by Movement Disorder Specialists?	Marzieh Keshtkarjahromi Disclosure: Dr. Keshtkarjahromi has nothing to disclose.
5:30 PM	062	Barriers to Vaccination in Homebound and Non-Homebound People with Parkinson's Disease	Jori Fleisher, MD, MSCE Disclosure: Dr. Fleisher has nothing to disclose.
5:30 PM	063	Traumatic brain injury and erectile dysfunction preceding clinically diagnosed alpha-synucleinopathies: a case - control study in Olmsted County, MN (1991-2010).	Shemonti Hasan Disclosure: Dr. Hasan has nothing to disclose.
5:30 PM	064	Objective Markers of Turning in Idiopathic Parkinson's Disease	Lakshmi Pillai Disclosure: Dr. Pillai has nothing to disclose.
5:30 PM	066	Prevalence and patterns of rest, postural and action tremor in drug-naive Parkinson's disease	Deepak Gupta, MD, MBBS Disclosure: Dr. Gupta has nothing to disclose.
5:30 PM	067	Experiences, impact, and communication of "off" periods in Parkinson's disease: qualitative experiences of patients and carepartners	Tara Rastgardani, MD Disclosure: Dr. Rastgardani has nothing to disclose.
5:30 PM	068	Characteristics of Patients with Parkinson Disease in Pakistan: Prospective Multicenter Cross-sectional Study	Wagma Shahzad Disclosure: Dr. Shahzad has nothing to disclose.
5:30 PM	069	Predictors of health-related quality of life in Parkinson's disease	Gregory Kuhlman, MD Disclosure: Dr. Kuhlman has nothing to disclose.
5:30 PM	070	Prenatal Exposure to Chlorpyrifos and Parkinson's risk: a prospective adolescent cohort evaluation	Sarah O'Shea, MD Disclosure: Dr. O'Shea has nothing to disclose.
5:30 PM	071	Primary Care Knowledge and Referral Practices Based on Early Symptoms of Parkinson's Disease	Stephanie Bissonnette, DO Disclosure: Dr. Bissonnette has nothing to disclose.
5:30 PM	072	Characterizing Types of Falls in Parkinson's Disease	Abraham Lieberman, MD, FAAN Disclosure: Dr. Lieberman has nothing to disclose.
5:30 PM	073	Healthcare Disparities in African-American Patients with Parkinson's Disease : A Comprehensive Literature Review and Call to Action	Shivani Naik Disclosure: Dr. Naik has nothing to disclose.
5:30 PM	074	Deeply Phenotyped Control Cohort for Studies of Parkinson's Disease	Rana Hanna AL-Shaikh Disclosure: Dr. Hanna AL-Shaikh has nothing to disclose.
5:30 PM	075	The Prevalence of Tandem Gait Abnormality in Parkinson's Disease	Jason Margolesky, MD Disclosure: Dr. Margolesky has nothing to disclose.
5:30 PM	076	Instructed Arm Swing Improves Walking Performance and Decreases Fall Risk in Individuals with Parkinsonism	Evan Fitzgerald Disclosure: Mr. Fitzgerald has nothing to disclose.
5:30 PM	077	Development of a Parkinson's Disease-Specific Admission Order Set	Danielle Larson, MD Disclosure:
5:30 PM	078	Sex Disparities in Health and Health Care Utilization after Parkinson Diagnosis: Rethinking PD Associated Disability	Michelle Fullard, MD Disclosure: Dr. Fullard has nothing to disclose.
5:30 PM	079	Characterization of variants in genes associated with Parkinson´s disease and parkinsonism in the African American population using exome sequencing	Angela Deutschlander, MD Disclosure: Dr. Deutschlander has nothing to disclose.
5:30 PM	080	Presentation of Parkinson's disease in patients originating of different geographical altitudes	Kelly Meza Capcha Disclosure: Dr. Meza Capcha has nothing to disclose.
5:30 PM	081	Differences in Quality of Life Between Men and Women with Parkinson's Disease	Medha Gudavalli Disclosure: Dr. Gudavalli has nothing to disclose.
5:30 PM	082	Predictors of Clinically Meaningful Change in PDQ-39 in Parkinson's Disease	Adam Margolius, MD Disclosure: Dr. Margolius has nothing to disclose.
5:30 PM	083	Use of a modified STROOP test to help with diagnosis in early idiopathic Parkinson's disease	Rebekah Langston Disclosure: Dr. Langston has nothing to disclose.
5:30 PM	084	NA	NA NA Disclosure:
Child Neurology and Developmental Neurology ePoster Session
Start Time	Pub.	Title	Presenter
5:30 PM	085	A splice-site mutation in USMG5 causes Leigh Syndrome due to lack of ATP synthesis	Emanuele Barca, MD Disclosure: Dr. Barca has nothing to disclose.
5:30 PM	086	Long-term Neurodevelopmental Outcomes in Preterm Infants with Posthemorrhagic Hydrocephalus Treated with Temporizing Devices	Lydia Bernhardt Disclosure: Dr. Bernhardt has nothing to disclose.
5:30 PM	087	Clinical profile and outcome of children with Lennox Gastaut Syndrome: Retrospective single centre cohort	Vishal Sondhi Disclosure: Dr. Sondhi has nothing to disclose.
5:30 PM	088	Iron and ferritin levels in patients with ADHD	Shreya Agarwal Disclosure: Dr. Agarwal has nothing to disclose.
5:30 PM	089	Unusual Presentation of Wilson Disease in a Pediatric Patient: Case Report	Michael DiSano, MD Disclosure: Dr. DiSano has nothing to disclose.
5:30 PM	090	Striatal Changes on MRI in Young Children with NMDAR: A Single Center Experience	Michael Nelson Disclosure: Dr. Nelson has nothing to disclose.
Pain and Palliative Care
Start Time	Pub.	Title	Presenter
5:30 PM	091	Gluten Neuropathy: Prevalence of Pain and the Role of Gluten-Free Diet.	Panagiotis Zis, MBBS, PhD Disclosure: Dr. Zis has nothing to disclose.
5:30 PM	093	ALS Patient Perspectives on Physician Assisted Death After Recent Passage of End of Life Options Act	Nicole Heinl Disclosure: Dr. Heinl has nothing to disclose.
5:30 PM	094	Prognostic Factors and Effectiveness of Percutaneous Balloon Compression in the Treatment of Trigeminal Neuralgia: An Experience of 222 patients	Sergio A. F. Dantas Disclosure: Dr. Adrian Fernandes Dantas has nothing to disclose.
5:30 PM	095	Evaluation of Pain Reproduction and other Predictive Factors of Selective Lumbar Nerve Block Efficacy for the Diagnosis and Palliative Treatment of Chronic Low Back Pain: A Retrospective Cohort Study	Yi Tong Disclosure: Dr. Tong has nothing to disclose.
5:30 PM	096	Widespread Myofascial Dysfunction and Regional Sensitization in Women with Endometriosis-associated Chronic Pelvic Pain	Barbara Karp, MD Disclosure: Dr. Karp has received research support from Allergan and Merz.
5:30 PM	098	Botulinum Toxin Treatment of Chronic Pelvic Pain in Women with Endometriosis	Barbara Karp, MD Disclosure: Dr. Karp has received research support from Allergan and Merz.
5:30 PM	099	Evaluation of Clinical Symptom and Signs Related to Histological and Functional Properties of Small Fiber Neuropathy in Diabetic Neuropathic Pain Patients	ISIN UNAL-CEVIK Disclosure: Dr. UNAL-CEVIK has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc.
5:30 PM	100	Polarity-specific Modulation of Central Pain Processing by Transcranial Direct Current Stimulation	Steffen Naegel, MD Disclosure: Dr. Naegel has nothing to disclose.
5:30 PM	102	Biotin-deficiency in patients with fibromyalgia syndrome combined with small fiber pathology.	Walter Maier-Janson, MD Disclosure: Dr. Maier-Janson has nothing to disclose.
5:30 PM	103	'Triggers' for a Palliative Care Service for Patients with Spinocerebellar Ataxia Type 1.	Patama Gomutbutra, MD Disclosure: Dr. Gomutbutra has nothing to disclose.
5:30 PM	104	Evaluation of Berberin- a Nrf2 Activator, on Paclitaxel-Induced Neuropathic Pain Model in Rat	amitava chakrabarti, MD, MBBS Disclosure: Dr. Chakrabarti has nothing to disclose.
5:30 PM	105	The Effectiveness of Spinal Cord Stimulation (SCS) In Reduction of Oral Opioid Use	Derek Yuan, MD Disclosure: Dr. Yuan has nothing to disclose.
5:30 PM	106	Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation for the Treatment of Fibromyalgia: An open label clinical trial	Levi H. Jales Jr. Disclosure: Dr. Higino Jales Junior has nothing to disclose.
5:30 PM	107	Successful Treatment of Refractory Trigeminal Neuralgia with Sphenopalatine Ganglion Block	Mohamed Binfalah Disclosure: Dr. Falah has nothing to disclose.
5:30 PM	108	Inflamed Brain: A Neuro-Palliative Approach	Justin Voorhees Disclosure: Dr. Voorhees has nothing to disclose.
Autonomic Disorders: Autonomic Neuropathies
Start Time	Pub.	Title	Presenter
5:30 PM	109	Autoimmune polyneuropathy with severe dysautonomia after ipilimumab treatment for melanoma	Kyle Kern, MD, MS Disclosure: Dr. Kern has nothing to disclose.
5:30 PM	110	A Case of Paraneoplastic Dysautonomia and Small Fiber Neuropathy	Jacob Didion, MD Disclosure: Dr. Didion has nothing to disclose.
5:30 PM	111	Diagnostic Utility of Sweat Gland Nerve Fiber Density in Small Fiber Neuropathy	Peter Novak, MD Disclosure: Dr. Novak has nothing to disclose.
5:30 PM	112	Dysautonomia in Charcot-Marie-Tooth Disease and Correlations with Patient-Reported Disability	Sindhu Ramchandren, MD Disclosure: Dr. Ramchandren has nothing to disclose.
5:30 PM	113	Small Fiber Neuropathy and Multiple Endocrinopathies with COX6A1 Gene Deletion	Glen Cook, MD Disclosure: Dr. Cook has nothing to disclose.
5:30 PM	114	Characterizing the spectrum of autonomic impairment in neurologic disorders with calcium channel antibodies	Julie Khoury, MD Disclosure: Dr. Khoury has nothing to disclose.
5:30 PM	115	Autonomic description in patients with very early TTR amyloidosis (Familial Amyloid Polyneuropathy).	Maria Alejandra Gonzalez Duarte, MD Disclosure: Dr. Gonzalez Duarte has nothing to disclose.
5:30 PM	116	The effect of vagal dysfunction on cytokine networks in HIV	Elizabeth Pedowitz, MD Disclosure: Dr. Pedowitz has nothing to disclose.
Autonomic Disorders: Other
Start Time	Pub.	Title	Presenter
5:30 PM	117	Healthcare Related Costs of Autonomic Disorders in MHS Beneficiaries	Agata Bogacki Disclosure: Dr. Bogacki has nothing to disclose.
5:30 PM	118	Progressive Multiple Sclerosis Patients Have a Higher Burden of Autonomic Dysfunction Compared to Relapsing Remitting Phenotype	Ivan Adamec Disclosure: Dr. Adamec has nothing to disclose.
5:30 PM	119	Psychosis in Multiple System Atrophy	Jose-Alberto Palma, MD, PhD Disclosure: Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.
5:30 PM	120	Long-term Fingolimod therapy increases sympathetic cardiovascular modulation	Ruihao Wang Disclosure: Dr. Wang has nothing to disclose.
5:30 PM	121	Cognitive impairment correlates with autonomic dysfunction in patients with a history of traumatic brain injury	Max J. Hilz, MD, PhD, FAAN Disclosure: Dr. Hilz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme. Dr. Hilz has received personal compensation in an editorial capacity for Autonomic Neuroscience: Basic and Clinical. Dr. Hilz has received research support from Novartis Pharma GmbH.
5:30 PM	122	Seasonal Hypothermia, Hypersomnolence, Encephalopathy, and Hypoventilation Following Hypothalamus Injury - A Case of Human Hibernation?	Leighton Mohl, MD Disclosure: Dr. Mohl has nothing to disclose.
5:30 PM	123	Three Shapiro Syndrome cases : diagnostic challenge of clinical spectrum of the spontaneous paroxysmal hypothermia syndrome	Rubens Salomao Disclosure: Dr. Salomão has nothing to disclose.
5:30 PM	124	Autonomic Dysfunction in Patients with Down Syndrome and Alzheimer Disease	Eric Huttler Disclosure: Dr. Huttler has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Orthostatic Intolerance
Start Time	Pub.	Title	Presenter
5:30 PM	125	Understanding the Symptoms of Neurogenic Orthostatic Hypotension: Results From a Survey of Patients and Caregivers	Satish R. Raj Disclosure: Dr. Raj has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott Laboratories, Boston Scientific Corporation, Lundbeck LLC, and GE Healthcare.
5:30 PM	126	Addressing Orthostatic Hypotension in Parkinson Disease Patients in a Neurology Resident Continuity Clinic	Elisabeth Golden, MD Disclosure: Dr. Golden has nothing to disclose.
5:30 PM	127	Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms	Daniel O. Claassen Disclosure: Dr. Claassen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Neuroscience, Lundbeck, Acadia, and AbbVie. Dr. Claassen has received research support from NIH/NINDS, Michael J. Fox Foundation, Huntington Disease Society of America, Vaccinex, AbbVie, and Auspex Pharmaceuticals.
5:30 PM	128	Patient and Caregiver Experiences With the Diagnosis of Neurogenic Orthostatic Hypotension	L. Arthur Hewitt Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck.
5:30 PM	129	Persistence of Droxidopa Treatment in Patients With Neurogenic Orthostatic Hypotension	Jan Basile Disclosure: Dr. Basile has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Arbor Pharmaceuticals, Janssen Pharmaceuticals and Lundbeck.
5:30 PM	130	Management and Treatment of Neurogenic Orthostatic Hypotension: Results From a Survey of Patients and Caregivers	L. Arthur Hewitt Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck.
5:30 PM	131	Short-Term Outcome in Children and Adolescents with Orthostatic Intolerance and Postural Tachycardia Syndrome	Imad Jarjour, MD, FAAN Disclosure: Dr. Jarjour has nothing to disclose.
5:30 PM	132	Joint Hypermobility is Related to Pathological Finding on Tilt Table Testing	Ivan Adamec Disclosure: Dr. Adamec has nothing to disclose.
5:30 PM	133	Running-Induced Vertigo in an Adolescent: A Treatable Orthostatic Vestibular Migraine Variant	Imad Jarjour, MD, FAAN Disclosure: Dr. Jarjour has nothing to disclose.
5:30 PM	134	Elevated Paraneoplastic Markers: An Uncommon Finding in Orthostatic Intolerance and Postural Orthostatic Tachycardia	Charlene Hoffman-Snyder Disclosure: Dr. Hoffman-Snyder has nothing to disclose.
5:30 PM	135	Postural Orthostatic Tachycardia: The Stanford experience	Safwan Jaradeh, MD, FAAN Disclosure: Dr. Jaradeh has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
5:30 PM	136	Isolated Sixth Cranial Nerve Palsy in Pregnancy	Noelia García Lax Disclosure: Dr. García Lax has nothing to disclose.
5:30 PM	137	A case of optic neuropathy due to cat scratch disease (CSD) and syphilis co-infection with characteristic MRI findings	MingYang Meah Gao, MD Disclosure: Dr. Gao has nothing to disclose.
5:30 PM	138	Wernicke's Encephalopathy After Hyperemesis Gravidarum	Pria Anand, MD Disclosure: Dr. Anand has nothing to disclose.
5:30 PM	139	A Case of Severe Wernicke Encephalopathy with Bilateral Sensorineural Hearing Loss	Michael Hansen Disclosure: Dr. Hansen has nothing to disclose.
5:30 PM	140	Objective Evidence of Hyper-rapid Olfactory Adaptation in Cranial Nerve I Dysfunction	Khurram Janjua Disclosure: Dr. Janjua has nothing to disclose.
5:30 PM	141	Hypereosinophilia and Neuro-ophthalmological manifestations in Lymphoma	Ehtesham Khalid, MBBS Disclosure: Dr. Khalid has nothing to disclose.
5:30 PM	142	Intraorbital Perineural Cyst of the Oculomotor Nerve	Laszlo Mechtler, MD, FAAN, FASN Disclosure: Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Philips, Allergan, Supernus, Avanir and Amgen. Dr. Mechtler has received personal compensation in an editorial capacity for Springer and Elsevier. Dr. Mechtler has received compensation for serving on the Board of Directors of MEND.
5:30 PM	143	Horner's Syndrome as the Presenting Symptom in Giant Cell Arteritis	Stephanie Figueira Disclosure: Dr. Figueira has nothing to disclose.
5:30 PM	144	Diplopia as the Presenting Symptom of Systemic T Cell Prolymphocytic Leukemia with Infiltration of the Superior Rectus Muscle.	Humaira Khan, MD Disclosure: Dr. Khan has nothing to disclose.
5:30 PM	145	Unilateral proptosis, scleral injection and superior gaze diplopia secondary to spontaneous ophthalmic artery to superior ophthalmic vein fistula - Case report and review of literature	Subin Mathew, MD Disclosure: Dr. Mathew has nothing to disclose.
5:30 PM	146	Development of Optic Neuritis after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, 1990-2017.	Janaki Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	147	Chronic Relapsing Inflammatory Optic Neuropathy	Chaitanya Amrutkar, MD Disclosure: Dr. Amrutkar has nothing to disclose.
5:30 PM	148	Intravenous immunoglobulin treatment in the management of corticosteroid unresponsive optic neuritis: A retrospective case series of 15 cases	Yu Zhao Disclosure: Dr. Zhao has nothing to disclose.
5:30 PM	149	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis	Soren Jonzzon Disclosure: Dr. Jonzzon has nothing to disclose.
5:30 PM	150	Audiological Profile of Multiple Sclerosis Patients in Jordan: A Case-Control Study.	Mohammad Alkhoujah Disclosure: Dr. Alkhoujah has nothing to disclose.
5:30 PM	152	Venous Sinus Stenting Improves Visual Fields and Cerebrospinal Fluid Opening Pressures in Patients with Idiopathic Intracranial Hypertension	Evan R Schloss, MD Disclosure: Dr. Schloss has nothing to disclose.
5:30 PM	153	Long-term Symptom Reduction of MdDS Rocking Vertigo with Theta Burst rTMS	Benjamin Chipper Doudican Disclosure: Dr. Doudican has nothing to disclose.
5:30 PM	154	'Sandbagging' a Vision Test for Concussion-based Sideline Assessment: An Eye Movement Investigation Objectively Reveals the 'Gamers' Strategies	Janet Rucker, MD Disclosure: Dr. Rucker has nothing to disclose.
5:30 PM	155	Field testing the ICHD 3 beta diagnostic criteria of vestibular migraine	Mark Obermann, MD Disclosure: Dr. Obermann has nothing to disclose.
5:30 PM	156	Psychological Measures of Individuals with Mal de Debarquement Syndrome	Diamond Gleghorn Disclosure: Dr. Urbano has nothing to disclose.
5:30 PM	157	Vestibular Perceptual Threshold and Motion Sensitivity in Vestibular Migraine and Persistent Postural-Perceptual Dizziness	Sebastian Wurthmann Disclosure: Dr. Wurthmann has nothing to disclose.
5:30 PM	158	Erlotinib-Induced Dandy's Syndrome: Case Report	Kristen Steenerson, MD Disclosure: Dr. Steenerson has nothing to disclose.
5:30 PM	159	Short-Term Memory Loss in Vestibular Patients can Arise Independently of Psychiatric Impairment, Fatigue and Sleeplessness	S.S. Surenthiran, MBBS Disclosure: Dr. Surenthiran has nothing to disclose.
5:30 PM	160	Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study	Rachel Nolan Disclosure: Dr. Nolan has nothing to disclose.
5:30 PM	161	Retinal Ganglion Cell Layer and Disease Activity in Clinically Isolated Syndrome	Hanna Zimmermann Disclosure: Dr. Zimmermann has nothing to disclose.
5:30 PM	162	Agonist of Growth Hormone Releasing Hormone (GHRH) Protects Retinal Ganglion Cells in a Model of Traumatic Optic Neuropathy	Christian Kim Disclosure: Dr. Kim has nothing to disclose.
5:30 PM	163	Evaluation of neuroprotective properties of dimethylfumarate by optical coherence tomography in non-inflammatory models of retinal neurodegeneration	Michael Dietrich Disclosure: Dr. Dietrich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
5:30 PM	164	Mkk4 and Mkk7 are Important for Both Retinal Development and Axonal Injury-Induced Retinal Ganglion Cell Death	Stephanie Syc Disclosure: Dr. Syc has nothing to disclose.
5:30 PM	165	Correlation of Visual Field Loss with MRI Findings in Patients with Pituitary Tumours	Christian Lueck, MD, FAAN Disclosure: Dr. Lueck has received research support from Perpetual.
5:30 PM	166	Impact of cataract surgery on cognitive functions in elderly patients presenting to a tertiary care center in Islamabad.	Faleha Zafar Disclosure: Dr. Zafar has nothing to disclose.
5:30 PM	167	Saccadic Intrusions Are Rare In Multiple Sclerosis	Lisa DePledge Disclosure: Dr. DePledge has nothing to disclose.
5:30 PM	168	Correlative Enhancement: Evaluation of a new postprocessing algorithm for diagnosis of optic neuritis.	Leanne Stunkel, MD Disclosure: Dr. Stunkel has nothing to disclose.
5:30 PM	169	The New MULES: A Sideline-Friendly Test of Rapid Picture Naming for Concussion	Omar Akhand Disclosure: Dr. Akhand has nothing to disclose.
5:30 PM	170	NA	NA NA Disclosure:
5:30 PM	171	NA	NA NA Disclosure:
5:30 PM	172	NA	NA NA Disclosure:
Behavioral and Cognitive Neurology: Genes, Environment, and Interventions
Start Time	Pub.	Title	Presenter
5:30 PM	173	Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype	John Parker, MD Disclosure: Dr. Parker has nothing to disclose.
5:30 PM	174	Huntington's disease across four generations in a mexican family: Westphal variant with female predominance	Jazmin Sotelo-Hernandez Disclosure: Dr. Sotelo-Hernandez has nothing to disclose.
5:30 PM	175	Fahr's disease due to a novel SLC20A2 gene mutation in a Canadian patient: Early Neurocognitive, Structural and Metabolic changes	Leila Sellami, MD Disclosure: Dr. Sellami has nothing to disclose.
5:30 PM	176	Two Distinct Clinical Phenotypes in a Family with ALSP Caused by a Novel CSF-1R Mutation.	Ryan Taylor, MD Disclosure: Dr. Taylor has nothing to disclose.
5:30 PM	177	A Case of AARS2 Leucoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL)	Michael Doyle, MRCPI Disclosure: Dr. Doyle has nothing to disclose.
5:30 PM	178	Correlation Between Exercise and Motor Skills with Elderly Patients Cognition	Cassio Henrique Taques Martins Disclosure: Dr. Martins has nothing to disclose.
5:30 PM	179	Dietary Approaches to Stop Hypertension (DASH) Diet Associated with Lower Rates of Depression	Laurel Cherian, MD Disclosure: Dr. Cherian has nothing to disclose.
5:30 PM	180	An Exploratory Analysis of Lifetime Surgical History and Cognition	James Bateman, MD Disclosure: Dr. Bateman has nothing to disclose.
5:30 PM	181	Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology	Matthew J Burke, MD Disclosure: Dr. Burke has nothing to disclose.
5:30 PM	182	'Just Google It' – The Effect of Media Events on Patterns of Public Interest in the 'Vaccines Cause Autism' Fallacy from 2004-2017	Shehryar Sheikh BA Disclosure: Dr. Sheikh has nothing to disclose.
Genetic and Basic Science Studies in Neurodegenerative Diseases
Start Time	Pub.	Title	Presenter
5:30 PM	183	Characterization of Regulatory T Lymphocytes in the progression of Alzheimer's Disease	Alirexa Faridar, MD Disclosure: Dr. Faridar has nothing to disclose.
5:30 PM	184	Age-Dependent White Matter Inflammation and Cognitive Impairment in the TgAPP21 Rat Model of Alzheimer Disease	Alexander Levit Disclosure: Dr. Levit has nothing to disclose.
5:30 PM	185	Case Control Study of RNA Editing in Blood Reveals Decreased Global Levels of A-to-I Editing in Alzheimer's Disease	Olivia Gardner Disclosure: Dr. Gardner has nothing to disclose.
5:30 PM	186	Genetic Basis of Motoric Cognitive Risk Syndrome in Health and Retirement Study	Sanish Sathyan Disclosure: Dr. Sathyan has nothing to disclose.
5:30 PM	187	Familial Adult-onset Neuronal Intranuclear Inclusion Disease	Monique Montenegro Disclosure: Dr. Montenegro has nothing to disclose.
5:30 PM	188	Amyloid-beta Induction of PIAS1 Ser-503 Phosphorylation and Elk-1 SUMOylation Mediate Endogenous Neuroprotection against Amyloid-beta Toxicity	Shau-Yu Liu Disclosure: Dr. Liu has nothing to disclose.
5:30 PM	189	Mutational Analysis of AARS2 in Japanese Patients with Adult-Onset Leukoencephalopathy Lacking CSF1R Mutation	Naomi Mezaki Disclosure: Dr. Mezaki has nothing to disclose.
5:30 PM	190	Identification and Functional Assay of Novel CSF1R Mutations in Patients with Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia	Takeshi MIURA Disclosure: Dr. Miura has nothing to disclose.
5:30 PM	191	Tau-related dysfunction of BRCA1 lead to reduced neuronal plasticity in Alzheimer's disease	Tatsuo Mano, MD, PhD Disclosure: Dr. Mano has nothing to disclose.
5:30 PM	192	Measuring the Contributions of Heritable and Non-Heritable Risk Factors to Alzheimer Disease Age-at-Symptomatic-Onset in Adult Children of Affected Parents	Gregory Day, MD, MSc Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health) and MedEdicus. Dr. Day holds stock and/or stock options in ANI Pharmaceuticals. Dr. Day has received research support from Avid Radiopharmaceuticals.
5:30 PM	193	Clinical and neuropsychological features of a family with a novel PSEN-1 variant (I416T)	Laura Ramírez-Aguilar Disclosure: Dr. Ramírez-Aguilar has nothing to disclose.
5:30 PM	194	Genome-wide Association Study Based on A/T/N System Identifies New Susceptibility Loci for Alzheimer's Disease	Chenchen Tan Disclosure: Dr. Tan has nothing to disclose.
5:30 PM	195	African Haplotypic Background Mitigates the Effect of APOE e4 Risk Allele in Alzheimer Disease	Farid Rajabli Disclosure: Dr. Rajabli has nothing to disclose.
5:30 PM	196	TREM2 P.Arg47His Is Not Associated With Late-Onset Alzheimer's Disease In A Tunisian Population	Mouna Ben Djebara Disclosure: Dr. Ben Djebara has nothing to disclose.
5:30 PM	197	In vitro, In vivo and cerebrospinal fluid studies implicate decreased ABCA-1 activity with APOE4	Varun Rawat Disclosure: Dr. Rawat has nothing to disclose.
5:30 PM	198	Case Report: SPG4-related cognitive decline in a patient with deletion of exons 5-17	Elizabeth Coffee Disclosure: Dr. Coffee has nothing to disclose.
5:30 PM	199	NA	NA NA Disclosure:
5:30 PM	200	NA	NA NA Disclosure:
Stroke Epidemiology, Risk Factors, and Outcomes
Start Time	Pub.	Title	Presenter
5:30 PM	201	Characterizing Stroke in Transgender Adults - a San Francisco General Hospital Study	Sara LaHue, MD Disclosure: Dr. LaHue has nothing to disclose.
5:30 PM	202	The Role of Acute versus Ever Use of Cocaine in Ischemic Stroke of Young Adults	Sleiman El Jamal, MD Disclosure: Dr. El Jamal has nothing to disclose.
5:30 PM	203	Code 420: A case series of accidental marijuana ingestion masquerading as acute stroke	Katherine Werbaneth, MD Disclosure:
5:30 PM	204	Recreational Use Of Marijuana and Stroke: A Nationwide Outcome Study	Urvish Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	205	Impact of Cocaine Use on Acute Ischemic Stroke Patients: Insights from Nationwide Inpatient Sample in the United States	Zabeend Mahuwala, MD Disclosure: Dr. Mahuwala has nothing to disclose.
5:30 PM	206	History of Diabetes, Drug Abuse and Smoking Predicts Recurrence Rate of Ischemic Stroke in the Young	Muhammad Ahmed, MD Disclosure: Dr. Ahmed has nothing to disclose.
5:30 PM	207	Continued Nationwide decline in Stroke related In-Hospital Mortality in United States	Mohammad Rauf Afzal Disclosure: Dr. Afzal has nothing to disclose.
5:30 PM	208	Clinical Characteristics of Stroke Patients with Essential Thrombocytosis according to JAK2 mutation	Joung-Ho Rha, MD, PhD Disclosure: Dr. Rha has nothing to disclose.
5:30 PM	209	Trauma due to Acute Ischemic Stroke: A Case Series	Kevin Yeboah, MD Disclosure: Dr. Yeboah has nothing to disclose.
5:30 PM	210	Only hepatic fibrosis, not steatosis, assessed on transient elastography is an independent predictor of long-term mortality in patients with ischemic stroke.	Minyoul Baik, MD Disclosure: Dr. Baik has nothing to disclose.
5:30 PM	211	Level of Consciousness at Discharge and Associations with Outcome After Ischemic Stroke	Michael Reznik, MD Disclosure: Dr. Reznik has nothing to disclose.
5:30 PM	212	Aphasia at Presentation Predicts Poor Functional Outcome After Acute Ischemic Stroke	Kathleen L. Donahue Disclosure: Dr. Donahue has nothing to disclose.
5:30 PM	213	Cancer and Stroke - Presentations and Problems	David Collas, MD Disclosure: Dr. Collas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer and Pfizer.
5:30 PM	214	Stroke in Teens	Chandramouleeswaran Venkatraman Disclosure: Dr. Venkatraman has nothing to disclose.
5:30 PM	215	Development and Validation of Graphical Displays for Reporting Acute Stroke Trials that Use a Patient-Centered Disability Outcome Primary Endpoint	Ivie Tokunboh Disclosure: Dr. Tokunboh has nothing to disclose.
5:30 PM	216	Classical Crossed Medullary Syndromes in Patients with Lateral Medullary Infarction	Guillermo Delgado-García Disclosure: Dr. Delgado-Garcia has nothing to disclose.
5:30 PM	217	Etiologies, risk factors and functional outcomes of young stroke in a Taiwanese cohort	Chun-Yu Chen Disclosure: Dr. Chen has nothing to disclose.
5:30 PM	218	Prevalence of HIV Infection Among Stroke Patients and its Association with Mortality in Southwestern Uganda	Amir Abdallah Disclosure: Dr. Abdallah has nothing to disclose.
5:30 PM	219	Incidence of Ischemic and Hemorrhagic Stroke Amongst Asians in the United States	Antonio Moya, MD Disclosure: Dr. Moya has nothing to disclose.
5:30 PM	220	Leukoaraiosis & Metabolic Syndrome In Middle Age Egyption Ischemic Stroke Patients	Wael Amer, MD Disclosure: Dr. Amer has nothing to disclose.
5:30 PM	221	Impact of Reactive Hyperglycemia on Stroke Severity and Outcome in Lagos, Nigeria	Osigwe Agabi, MD Disclosure: Dr. Agabi has nothing to disclose.
5:30 PM	222	Predictors of Stroke Recurrence at Lagos University Teaching Hospital,Nigeria.	Nosakhare Osemwegie Disclosure: Dr. Nosakhare has nothing to disclose.
5:30 PM	223	Clinical characteristics of borderzone infarction in Egyptian population	Nevine EL Nahas Disclosure: Dr. EL Nahas has nothing to disclose.
Stroke Biomarkers and Animal Models
Start Time	Pub.	Title	Presenter
5:30 PM	224	Neurovascular Protective Effects of Remote Ischemic Preconditioning in Acute Ischemic Stroke Model	Farris Taha Disclosure: Dr. Taha has nothing to disclose.
5:30 PM	225	Functional Remapping of the Mouse Somatosensory Cortex After Ischemic Stroke	William Zeiger, MD, PhD Disclosure: Dr. Zeiger has nothing to disclose.
5:30 PM	226	Multimodal Imaging of White Matter Inflammation in a Rat Model of Striatal Ischemic Stroke	Alexander Levit Disclosure: Dr. Levit has nothing to disclose.
5:30 PM	227	Blockade of Soluble Epoxide Hydrolase Attenuates Post-Ischemic Neuronal Hyperexcitation and Confers Resilience Against Stroke with TrkB Activation	Li-Hsin Chang Disclosure: Dr. Chang has nothing to disclose.
5:30 PM	228	Characterizing the Neuroinflammatory Response of Focal Ischemic Stroke in the Rat Insular Cortex	Victoria Thorburn Disclosure: Dr. Thorburn has nothing to disclose.
5:30 PM	229	Association of plasma D-dimer and B-type natriuretic peptide levels with stroke mechanism, severity, and outcome	Hyun-Wook Nah Disclosure: Dr. Nah has nothing to disclose.
5:30 PM	230	Role Of Blood Biomarkers In Differentiating Ischemic Stroke and Intracerebral Hemorrhage	Rohit Bhatia, MBBS,MD,DM Disclosure: Dr. Bhatia has nothing to disclose.
5:30 PM	231	Circulating inflammatory biomarkers are related to cerebrovascular disease in a non-demented elderly population	Yian Gu, PhD,DrPH Disclosure: Dr. Schupf has nothing to disclose.
5:30 PM	232	Diapedetic Potential of Monocytes in Complexes with Platelets Correlates with Clinical Outcome after Stroke	Maria Lukasik Disclosure: Dr. Lukasik has nothing to disclose.
5:30 PM	233	Multiple Biomarkers for the Prediction of Stroke Outcomes: Findings from a Cohort of 792 Patients with Ischemic Stroke in a University Teaching Hospital	Zuolu Liu Disclosure: Dr. Liu has nothing to disclose.
5:30 PM	234	Role Of Blood Biomarkers In Predicting Outcomes After Acute Stroke	Divya M Radhakrishnan Disclosure: Dr. MR has nothing to disclose.
5:30 PM	235	Marked Leukocytosis on Presentation with Acute Ischemic Stroke -- What Does it Mean?	Matthew Broderick, MD Disclosure: Dr. Broderick has nothing to disclose.
5:30 PM	236	Admission white blood cell count is associated with stroke severity and outcome independent of acute infarct size	Anne-Katrin Giese Disclosure: Dr. Giese has nothing to disclose.
5:30 PM	237	Can S100b, IL 6 And BNP Predict Functional Neurological Outcome In Intracerebral Hemorrhage?	Mohammed El-Sherif, MD Disclosure: Dr. El-Sherif has nothing to disclose.
5:30 PM	238	Role of Copeptin as a Biomarker for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: A Prospective Cohort Study	Shubham Misra Disclosure: Dr. Misra has nothing to disclose.
5:30 PM	239	Role of Blood Based Biomarkers for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: Findings from a Multi-Centric Prospective Cohort Study	Kameshwar Prasad, MD Disclosure: Dr. Prasad has nothing to disclose.
5:30 PM	240	A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Ischemic Stroke	I-Chen Yu Disclosure: Dr. Yu has nothing to disclose.
Cerebrovascular Genetics
Start Time	Pub.	Title	Presenter
5:30 PM	241	Molecular Genetic Features Of Polymorphism Of The Gene Col4a1 Rs605143 G / A In The Development Of Pathological Deformations Of Cerebral Vessels In Patients With Migraine	Gulnora Rahmatullaeva Disclosure: Dr. Rahmatullaeva has nothing to disclose.
5:30 PM	242	The Cerebral Straight and Narrow: A Case Illustration of Moyamoya Syndrome in the Setting of the ACTA-2 Gene Mutation	Malcolm McDonald Disclosure: Dr. McDonald has nothing to disclose.
5:30 PM	243	Rare Presentation of Malignant Myxomatous Aneurysms with PRKAR1A gene mutation	Usman Shehzad, MD Disclosure: Dr. Shehzad has nothing to disclose.
5:30 PM	244	Molecular - Genetic Features Of The Gene Of Vasculoendothelial Growth Factor (C634G VEGFA) In The Deformations Of Cerebral Vessels	Gulnora Rahmatullaeva Disclosure: Dr. Rahmatullaeva has nothing to disclose.
5:30 PM	245	PAI-1 polymorphism and stroke in pregnancy	Mary Hollist, DO, MD Disclosure: Dr. Hollist has nothing to disclose.
5:30 PM	246	Ring-enhancing lesions, stroke and vascular retinopathy associated with a novel TREX1 mutation	Marcus Cimino, MD Disclosure: Dr. Cimino has nothing to disclose.
5:30 PM	247	Systemic Response to Rupture of Intracranial Aneurysms Analyzed with Whole-transcriptome Sequencing	Joanna Pera, MD Disclosure: Dr. Pera has nothing to disclose.
5:30 PM	248	Association of Transforming growth Factor-?1 gene C509T, G800A and T869C Polymorphisms with Intracerebral Hemorrhage in North Indian Population: A Case-Control Study	Shubham Misra Disclosure: Dr. Misra has nothing to disclose.
5:30 PM	249	Role Of Pharmacogenetics and Pharmacodynamics On The Antiplatelet Effect Of Clopidogrel In North Indian Ischemic Stroke Patients	Dheeraj Khurana, MD Disclosure: Dr. Khurana has nothing to disclose.
5:30 PM	250	Association between Tumor necrosis factor-alpha (-308G/A, +488G/A, -857C/T and -1031 T/C) gene polymorphisms and risk of ischemic stroke in north Indian population: A case-control study	Pumanshi Talwar Disclosure: Dr. Talwar has nothing to disclose.
Pre-Hospital, Telestroke and ED-Based Stroke Care II
Start Time	Pub.	Title	Presenter
5:30 PM	251	Safety and Feasibility of Telestroke in the Prehospital Emergency Medical Services Setting - The REACHOUT Project	Muhammad Adeel Saleemi Disclosure: Dr. Saleemi has nothing to disclose.
5:30 PM	252	Pre-arrival RACE Score-Based Hospital Bypass Protocol Improves Treatment Time Efficiencies	Shazli Khan Disclosure: Dr. Khan has nothing to disclose.
5:30 PM	253	Correlation between evaluation and documentation of neurologic deficit by EMS and ED of patients with acute ischemic stroke	Haitham Hussein, MD Disclosure: Dr. Hussein has nothing to disclose.
5:30 PM	254	A Prospective Validation of Stroke Network Of Wisconsin (SNOW) Scale	Kessarin Panichpisal Disclosure: Dr. Panichpisal has nothing to disclose.
5:30 PM	255	Safety of intravenous thrombolysis in telestroke and impact of an acute stroke training curriculum	Tarun Girotra, MD Disclosure: Dr. Girotra has nothing to disclose.
5:30 PM	256	NA	NA NA Disclosure:
5:30 PM	257	NA	NA NA Disclosure:
5:30 PM	258	NA	NA NA Disclosure:
Clinical Epilepsy II
Start Time	Pub.	Title	Presenter
5:30 PM	259	Baroreflex Sensitivity in Patients with Intractable Generalized Tonic Clonic Seizures versus Partial Seizures	Behnaz Esmaeili, MD Disclosure: Dr. Esmaeili has nothing to disclose.
5:30 PM	260	Evaluation of Dual Pathology Among Drug Resistant Epileptic Patients With Hippocampal Sclerosis	Peyman Gookizadeh Disclosure: Dr. Gookizadeh has nothing to disclose.
5:30 PM	261	A New Database Platform for Clinical and Genetic Investigation of Epilepsies and the New ILAE Classification	David Discua Disclosure: Dr. Discua has nothing to disclose.
5:30 PM	262	Initial Presentations and Surgical Outcomes of Pediatric Patients with Neurovascular Lesions	Janani Kassiri, MD, PhD Disclosure: Dr. Kassiri has nothing to disclose.
5:30 PM	263	Comparing the Clinical Profile and Seizure Control between Focal and Generalized Seizures in Adult Nigerian Patients with Epilepsy.	Chindo Mallum, MD Disclosure: Dr. Mallum has nothing to disclose.
5:30 PM	264	A Fatal Case of Mistaken Identity: Brugada Syndrome Masquerading as Seizure Disorder	Claribel Wee, MD Disclosure: Dr. Wee has nothing to disclose.
5:30 PM	265	Impact of Seizures in Temporal Lobe Epilepsy on Cognitive Functions and Imaging Features	Gyujoon Hwang Disclosure: Dr. Hwang has nothing to disclose.
5:30 PM	266	Clinical Significance of Bilateral Failures on Wada Memory Testing	Iffat Ara Suchita, MD Disclosure: Dr. Suchita has nothing to disclose.
5:30 PM	267	Seizure-induced Behavioral and Autonomic Arousal Localizes to the Anterior Cingulate Gyrus: Network Dynamics and Underlying Mechanism	Harshad Ladha, MD Disclosure: Dr. Ladha has nothing to disclose.
5:30 PM	268	Does A Drug Refractory Epilepsy (DRE) diagnosis impact time to seizures in the Epilepsy Monitoring Unit (EMU)	Brian Toh Disclosure: Dr. Toh has nothing to disclose.
5:30 PM	269	The Role Of Immunoreactivity Of Neurotropic Autoantibodies And Neuromediators In The Pathogenesis Of Symptomatic And Idiopathic Epilepsy	Marufjon Salokhiddinov Disclosure: Dr. Salokhiddinov has nothing to disclose.
5:30 PM	270	Epilepsy as a Dynamic Disease: Modeling Seizure Burden Based On Transitions Between Seizure Risk States	Sharon Chiang Disclosure: Dr. Chiang has nothing to disclose.
5:30 PM	271	Effect of Anesthesia on Electrocorticography for localization of Epileptic Focus: Literature Review and Future Directions	Ayse Bayram Disclosure: Dr. Bayram has nothing to disclose.
5:30 PM	272	Can We Predict the prognosis in patients with Acute Symptomatic Seizure? A Prognostic model: A Retrospective study from a developing nation	GOPAL KRISHNA DASH Disclosure: Dr. Dash has nothing to disclose.
Epilepsy: Basic Science and Genetics
Start Time	Pub.	Title	Presenter
5:30 PM	273	Characterization of a Novel Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy	Lisseth Burbano Disclosure: Dr. Burbano has nothing to disclose.
5:30 PM	274	NLRP1 Inflammasome is Activated in Patients with Medial Temporal Lobe Epilepsy and Contributes to Neuronal Pyroptosis in Amygdala Kindling- induced Rat Model	Chenchen Tan Disclosure: Dr. Tan has nothing to disclose.
5:30 PM	275	Autophagy in Juvenile Myoclonic Epilepsy (JME)	Miyabi Tanaka Disclosure: Dr. Tanaka has nothing to disclose.
5:30 PM	276	NADPH oxidase inhibitor attenuated increased seizure susceptibility after systemic inflammation	Wan-Yu Huang Disclosure: Dr. Huang has nothing to disclose.
5:30 PM	277	A role of GPR55 in the antiepileptic properties of cannabidiol (CBD)	Benjamin J. Whalley Disclosure: Dr. Whalley is employed by GW Pharmaceuticals. Dr. Whalley holds stock and/or stock options in GW Pharmaceuticals, which sponsored research in which Dr. Whalley was involved as an investigator.
5:30 PM	278	Variation in Cortical Impact Augments Epileptogenesis in Rat Model of Traumatic Brain Injury.	SHAMMY CHANDEL Disclosure: Dr. Chandel has nothing to disclose.
5:30 PM	279	Protective effects of protocatechuic acid against seizure-induced neuronal death in the pilocarpine-induced status epilepticus rat model	Dong Jin Shin, MD Disclosure: Dr. Shin has nothing to disclose.
5:30 PM	280	Association Between Occurrence of Hippocampal Spindles and Hippocampal Interictal Spiking.	Kseniia K. Kriukova Disclosure: Dr. Kriukova has nothing to disclose.
5:30 PM	281	Majority of Epilepsy Mutations are in Genes with Therapeutic Associations	Elaine Weltmer Disclosure: Dr. Weltmer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ambry Genetics.
5:30 PM	282	Genotype and Phenotype Correlation in Patients with Comorbid Epilepsy and Intellectual Disability	Mohamed Taha, MD Disclosure: Dr. Taha has nothing to disclose.
5:30 PM	283	Screening of PI3K-AKT-mTOR pathway genes in focal cortical dysplasias in a clinical setting	Andrea Accogli Disclosure: Dr. Accogli has nothing to disclose.
5:30 PM	286	Prevalence and Impact of Consanguinity in Patients with Mesial Temporal Sclerosis in Saudi Population	Khalid Alqadi, MD Disclosure: Dr. Alqadi has nothing to disclose.
5:30 PM	287	Refractory Status Epilepticus and Chronic Kidney Disease in a Large Pedigree Due to a Variant in the Mitochondrial Encoded tRNA Phenylalanine (MT-TF) Gene	James H. Ellis, BS Disclosure: Dr. Ellis has nothing to disclose.
5:30 PM	288	Analysis of 234 Epilepsy Genes for Sequence and Copy Number Variants Using Next Generation Sequencing	Zhenyuan Wang Disclosure: Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Quest Diagnostics. Dr. Wang has received research support from Quest Diagnostics.
5:30 PM	289	Genetic Testing has taken out Guesswork: Cases of Familial and Non-familial Benign Infantile Epilepsy Associated with PRRT2 gene mutations.	Yoshimi Hisamoto, MD Disclosure: Dr. Hisamoto has nothing to disclose.
5:30 PM	290	NA	NA NA Disclosure:
5:30 PM	291	NA	NA NA Disclosure:
5:30 PM	292	NA	NA NA Disclosure:
5:30 PM	293	NA	NA NA Disclosure:
5:30 PM	294	NA	NA NA Disclosure:
Child Neurology and Developmental Neurology: Epilepsy
Start Time	Pub.	Title	Presenter
5:30 PM	295	EEG Patterns in Routine Polysomnography in Childhood and Risk of Epilepsy	Robert Stowe, MD Disclosure: Dr. Stowe has nothing to disclose.
5:30 PM	296	New Onset Refractory Status Epilepticus in Pediatric Population: A Single Tertiary Center Experience	Khalil Husari, MD Disclosure: Dr. Husari has nothing to disclose.
5:30 PM	297	Cognitive, Linguistic and Behavioral Characteristics of Children with Comorbid Autism Spectrum Disorder and Epilepsy	Louisa Kalsner, MD Disclosure: Dr. Kalsner has nothing to disclose.
5:30 PM	298	Evaluation of new onset seizures presenting to the Pediatric Emergency Department(ED). A quality improvement study based on the AAN, CNS and AES practice parameters (2010).	Nitish Chourasia, MD Disclosure: Dr. Chourasia has nothing to disclose.
5:30 PM	299	Cognitive Outcomes In Children With Infantile Spasms: Successful Treatment Response Is Beneficial Regardless Of Etiology	Nonita Mittal, MBBS Disclosure: Dr. Mittal has nothing to disclose.
5:30 PM	300	The clinical and electroencephalographic spectrum of ESES (Encephalopathy with status epilepticus in sleep) in Indian children	Priyanka Madaan Disclosure: Dr. Madaan has nothing to disclose.
5:30 PM	301	Long-Term Prognostic Patterns In Pediatric Epilepsy: A Review Of Literature.	Kushal Naik Disclosure: Dr. Naik has nothing to disclose.
5:30 PM	302	Rectal Administration of Vigabatrin Achieves Higher Plasma Concentration than Oral Administration.	Mohammad Hamed Disclosure: Dr. Hamed has nothing to disclose.
5:30 PM	303	Utilizing Quality Improvement Strategies to Increase Continuous EEG Monitoring in Critically Ill Pediatric Patients with Persistent Encephalopathy Following Status Epilepticus	Asri Yuliati Disclosure: Dr. Yuliati has nothing to disclose.
5:30 PM	304	Expanding the clinical spectrum of the rare epilepsy syndrome of Benign Infantile Focal Epilepsy with Midline Spikes (BIMSE)	Reema Butt Disclosure: Dr. Butt has nothing to disclose.
5:30 PM	305	Drug-Resistant Epilepsy and Neurodevelopmental Disabilities in Randomized Controlled Trials of Therapeutic Devices	Lydia Bernhardt Disclosure: Dr. Bernhardt has nothing to disclose.
Child Neurology and Developmental Neurology: Infectious, Inflammatory, and Autoimmune Disorders
Start Time	Pub.	Title	Presenter
5:30 PM	306	The Spectrum of Myelopathies in Children: Beyond Idiopathic Transverse Myelitis	Laura Munoz-Arcos, MD Disclosure: Dr. Munoz-Arcos has nothing to disclose.
5:30 PM	307	Cerebrospinal fluid (CSF) Neurofilament and CXCL-13 Levels in Children with Demyelinating Disease	Maria Galardi Disclosure: Dr. Galardi has nothing to disclose.
5:30 PM	308	Pediatric and Adult MS: A Longitudinal Multimodal MRI Study to Explore the Substrates of the Different Clinical Courses	Ermelinda De Meo Disclosure: Dr. De Meo has nothing to disclose.
5:30 PM	309	Chitinase 3-like 1 and Neurofilament Light Chain Predict Pediatric Demyelination	Magnus Spangsberg Boesen Disclosure: Dr. Spangsberg Boesen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva and Novartis. Dr. Spangsberg Boesen has received research support from Teva, Novartis, and Genzyme.
5:30 PM	310	CT Scan Findings in Microcephaly Cases During 2015-2016 Zika Outbreak: A Cohort Study	Tabata De Alcantara Disclosure: Dr. De Alcantara has nothing to disclose.
5:30 PM	311	Use of Induction Immunotherapy Plus Rituximab for the Treatment of Pediatric Opsoclonus-Myoclonus Syndrome	Colin Wilbur, MD Disclosure: Dr. Wilbur has nothing to disclose.
5:30 PM	312	To determine the prevalence of neurologic syndromes, intellectual disability, abnormal behavior and sleep related problems in HIV infected children	Rajni Farmania Disclosure: Dr. Farmania has nothing to disclose.
5:30 PM	313	Autoimmune encephalitis in children: Clinical profile and outcome from a single tertiary care centre in India	Sheffali Gulati Disclosure: Dr. Gulati has nothing to disclose.
5:30 PM	314	Radiological Findings and Neurological Disorders in Microcephaly Cases Related to Zika Virus: A Cohort Study	Tabata De Alcantara Disclosure: Dr. De Alcantara has nothing to disclose.
5:30 PM	315	Gait variability is related to attention and information processing speed in adolescents with multiple sclerosis	Shay Menascu Disclosure: Dr. Menascu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme and Merck/EMD Serono.
5:30 PM	316	A Case of Cognitive and Behavioral Decline leading to Onset of Pediatric Onset Multiple Sclerosis	Janet Elgallab, MD Disclosure: Dr. Elgallab has nothing to disclose.
5:30 PM	317	A Case Series of Acute Flaccid Myelitis in Pediatric Patients	Lydia Marcus, MD Disclosure: Dr. Marcus has nothing to disclose.
5:30 PM	318	Imaging of the Mechanisms of Thalamic Damage in Pediatric Multiple Sclerosis	Ermelinda De Meo Disclosure: Dr. De Meo has nothing to disclose.
5:30 PM	319	Miller Fisher Syndrome in a Case of Identical Twins	Tayyba Anwar, MD Disclosure: Dr. Anwar has nothing to disclose.
5:30 PM	320	Pediatric Acute Flaccid Myelitis: A Case Series	Alison Christy, MD, PhD Disclosure: Dr. Christy has nothing to disclose.
5:30 PM	321	Chiari malformations associated with transverse myelitis: are these myelopathies truly inflammatory?	Eliza Gordon-Lipkin, MD Disclosure: Dr. Gordon-Lipkin has nothing to disclose.
Child Neurology and Developmental Neurology: Neuromuscular Disease
Start Time	Pub.	Title	Presenter
5:30 PM	322	Ambulatory function and fatigue in nusinersen-treated children with spinal muscular atrophy.	Jacqueline Montes, PT, EdD, NCS Disclosure: Dr. Montes has received personal compensation for activities compensation for consulting, serving on a scientific advisory board, speaking, or other activities with ISIS Pharmaceuticals, Inc.
5:30 PM	323	Safety profile of abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials	Ann Tilton, MD, FAAN Disclosure: Dr. Tilton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Tilton has received research support from Ipsen Pharma.
5:30 PM	324	Safety and Efficacy of Nusinersen in Infants/Children with Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study	Perry B. Shieh, MD, PhD Disclosure: Dr. Shieh has nothing to disclose.
5:30 PM	325	Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy	Basil Darras, MD Disclosure: Dr. Darras has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Cytokinetics, Marathon Pharmaceuticals, PTC Therapeutics, Roche, Sarepta, Bristol-Myers Squibb, and Ionis Pharmaceuticals, Inc. Dr. Darras has received research support from Ionis Pharmaceuticals, Inc. for the ENDEAR, CHERISH, CS2/CS12 studies, from Biogen for CS11 , as well as from Cytokinetics, PTC Therapeutics, Fibrogen, and Summit.
5:30 PM	326	Pediatric Myasthenia Gravis After Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990-2017)	Rajanigandhi Hanumanthu, MD Disclosure: Dr. Hanumanthu has nothing to disclose.
5:30 PM	327	Evaluation of Childhood Weakness: Utilization of a Web-Based Educational Tool childmuscleweakness.org	Ann Martin Disclosure: Dr. Martin has nothing to disclose.
5:30 PM	328	Predicting Ambulatory Aid Needs with Disease Progression in Charcot-Marie-Tooth Disease	Sindhu Ramchandren, MD Disclosure: Dr. Ramchandren has nothing to disclose.
5:30 PM	329	Design of a Phase 3 Trial to Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy	Panayiota Trifillis Disclosure: Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc.
5:30 PM	330	Assessment of Practice Patterns and Knowledge of Pathophysiology for Spinal Muscular Atrophy Among Neurologists	John Maeglin Disclosure: Dr. Maeglin has nothing to disclose.
5:30 PM	331	Slope Analysis of 6-Minute Walk Dstance as an Alternative Method to Determine Treatment Effect in Trials in Duchenne Muscular dystrophy	Panayiota Trifillis Disclosure: Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc.
5:30 PM	332	Tolerability of Eteplirsen for Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy	Sonam Bhalla, MD Disclosure: Dr. Bhalla has nothing to disclose.
5:30 PM	333	Cervical Puncture to Deliver Nusinersen in Patients with Spinal Muscular Atrophy and no Lumbar Access	Aravindhan Veerapandiyan, MD Disclosure: Dr. Veerapandiyan has nothing to disclose.
5:30 PM	334	A unique presentation of rapidly fluctuating symptoms in a child diagnosed with Congenital Myasthenic Syndrome due to RAPSN mutation.	Ashutosh Kumar, MD Disclosure: Dr. Kumar has received research support from Marathon and Sarepta Therapeutics.
5:30 PM	335	Focal Myositis of the Iliopsoas in a Young Girl with Recurrent Symptoms: A Case Report	Stephanie Manberg, DO Disclosure: Dr. Manberg has nothing to disclose.
5:30 PM	336	Unexpected Neuromuscular Diagnoses from Chromosomal Microarrays	Rebecca Luke, DO Disclosure: Dr. Luke has nothing to disclose.
5:30 PM	337	NA	NA NA Disclosure:
5:30 PM	338	NA	NA NA Disclosure:
Epilepsy/Clinical Neurophysiology (EEG) ePoster Session
Start Time	Pub.	Title	Presenter
5:30 PM	339	Seizure Risk From Intraoperative Motor Evoked Potential Stimulation	Viet Nguyen, MD Disclosure: Dr. Nguyen has nothing to disclose.
5:30 PM	340	Mesial Temporal Sclerosis (MTS) Undetected by MRI of the Brain	Miad Albalawi, MD Disclosure: Dr. Albalawi has nothing to disclose.
5:30 PM	341	Long Term Effects of Vagal Nerve Stimulation on Seizure Control and Quality of Life	Justin Abraham, MD Disclosure: Dr. Abraham has nothing to disclose.
5:30 PM	342	Unilateral deep brain stimulation masks undiagnosed epilepsy in a Parkinson's Disease patient: A Case Report	Alexis Taylor Disclosure: Dr. Taylor has nothing to disclose.
5:30 PM	343	EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus	Jake McKay, MD Disclosure: Dr. McKay has nothing to disclose.
5:30 PM	344	Analyzing Phenotypes Using Artificial Intelligence Tools in Subgroups of Absence and Myoclonic Epilepsies	Reyna M. Durón Disclosure: Dr. Duron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbot.
MS Modifiable Risk Factors
Start Time	Pub.	Title	Presenter
5:30 PM	345	Hypertension and heart disease are independently associated with development of brain atrophy in multiple sclerosis patients. A 5-year longitudinal study	Dejan Jakimovski Disclosure: Dr. Jakimovski has nothing to disclose.
5:30 PM	346	The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis.	Saul Reyes Disclosure: Dr. Reyes has nothing to disclose.
5:30 PM	347	Vitamin D and physical activity in multiple sclerosis	Florian Deisenhammer, MD Disclosure: Dr. Deisenhammer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and TEVA. Dr. Deisenhammer has received research support from by Biogen and Genzyme-Sanofi..
5:30 PM	348	Depression Severity Among Multiple Sclerosis Patients In Saudi Arabia-Cross Sectional Study	Adel Ali Alhazzani Disclosure: Dr. Alhazzani has nothing to disclose.
5:30 PM	349	Vitamin B12 and its impact on Multiple Sclerosis Type and Severity	Shymaa Buhlaiqah Disclosure: Dr. Hussain has nothing to disclose.
5:30 PM	350	Cesarean delivery and artificial lactation are associated with an earlier age of disease onset in multiple sclerosis	Vittorio Martinelli Disclosure: Dr. Martinelli has nothing to disclose.
5:30 PM	351	Distinct Effects of Obesity and Vitamin D on Risk of Multiple Sclerosis: A Mendelian Randomization Study	Adil Harroud, MD Disclosure: Dr. Harroud has nothing to disclose.
5:30 PM	352	Vitamin D Levels and Clinical and OCT measures in Progressive Multiple Sclerosis	Justin Abbatemarco, MD Disclosure: Dr. Abbatemarco has nothing to disclose.
5:30 PM	353	Longer Sleep Duration is Linked to Preserved Cortical Gray Matter Volume in Early MS	Michelle Fabian, MD Disclosure: Dr. Fabian has nothing to disclose.
5:30 PM	354	Risk Factors Associated with Multiple Sclerosis in Bogotá, Colombia.	Jaime Toro, MD, FAAN Disclosure: Dr. Toro has received personal compensation in an editorial capacity for New England Journal of Medicine, Journal Watch Neurology and Multiple Sclerosis and Related Disorders.
5:30 PM	355	The Gut Microbiome in Relapsing Multiple Sclerosis Patients Compared to Controls.	Raffaella Umeton, MD Disclosure: Dr. Umeton has nothing to disclose.
5:30 PM	356	Fecal Microbial Transplantation in Multiple Sclerosis: trial design.	Ana Cristina Wing Disclosure: Dr. Dos Santos has nothing to disclose.
5:30 PM	357	Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome	Simona Rolla Disclosure: Dr. Rolla has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme.
5:30 PM	358	A Paleolithic Diet-Based Intervention Decreases Multiple Sclerosis Fatigue via Lipid Profile Changes	Murali Ramanathan, PhD Disclosure: Dr. Ramanathan has nothing to disclose.
5:30 PM	359	Stress-induced Brain Activity, Brain Atrophy, and Clinical Disability in Multiple Sclerosis	Lil Meyer-Arndt Disclosure: Dr. Meyer-Arndt has nothing to disclose.
5:30 PM	360	Case Series of Four High School Football Players with Multiple Sclerosis	Cynthia Wang, MD Disclosure: Dr. Wang has nothing to disclose.
5:30 PM	361	Nutrition in the First Year Following the Diagnosis of Multiple Sclerosis	Yujie Wang, MD Disclosure: Dr. Wang has nothing to disclose.
MS Diagnosis, Mimickers, and Phenotypes
Start Time	Pub.	Title	Presenter
5:30 PM	362	Sarcoidosis Presenting as Intramedullary Spinal Cord Lesions	Prateek Thatikunta Disclosure: Dr. Thatikunta has nothing to disclose.
5:30 PM	363	When It's Not Multiple Sclerosis: Progressive White Matter Lesions with Inflammation	Julia Bucklan, DO Disclosure: Dr. Bucklan has nothing to disclose.
5:30 PM	364	Comorbidity in ultiple Sclerosis is associated with Diagnostic Delays and Increased Mortality	Anja Thormann Disclosure: Dr. Thormann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adelphi Communications Ltd..
5:30 PM	365	Population-Based Prospective Cohort of RRMS Patients Who Declined or Delayed Disease-Modifying Therapy	Abdulaziz Al Sultan Disclosure: Dr. Al Sultan has nothing to disclose.
5:30 PM	366	Assessment of Relative Importance of Disease Modifying Treatment (DMT) Attributes in Multiple Sclerosis (MS) Patients	Tobias Sejbaek Disclosure: Dr. Sejbaek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck, Novartis, and Teva.
5:30 PM	367	Late Onset Fabry Disease: A Mimicker of CNS Demyelinating Disease	Subhendu Rath, MBBS Disclosure: Dr. Rath has nothing to disclose.
5:30 PM	368	The phenotype of Argentinean Multiple Sclerosis patients is similar to Multiple Sclerosis patients from other regions and has remained stable over the past decade.	Mariano Marrodan Disclosure: Dr. Marrodan has nothing to disclose.
5:30 PM	369	Impact of Gender on 30-day Readmission After Primary Admissions for Multiple Sclerosis: A Nationwide Readmission Database Analysis	Smit Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	370	Residual disability of acute severe multiple sclerosis relapses	Anat Achiron, MD, PhD, FAAN Disclosure: Dr. Achiron has nothing to disclose.
5:30 PM	371	Clinical and Immunologic Characterization of MRI-Defined Phenotypes in Multiple Sclerosis: a Longitudinal Study	Christopher Hemond, MD Disclosure: Dr. Hemond has nothing to disclose.
5:30 PM	372	Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL): A Rare Familial Mimic of Tumefactive Multiple Sclerosis (MS)	Asaff Harel, MD Disclosure: Dr. Harel has nothing to disclose.
5:30 PM	373	An Extremely Aggressive case of Marburg's Disease	Jose Avila-Ornelas, MD Disclosure: Dr. Avila-Ornelas has nothing to disclose
5:30 PM	374	Spectrum of Peripheral Facial Involvement in Central Demyelinating Diseases	Elias Samaha, MD Disclosure: Dr. Samaha has nothing to disclose.
MS Epidemiology and Genetics
Start Time	Pub.	Title	Presenter
5:30 PM	375	Impact of age at relapse on recovery: An EDSS-recovery model for clinical trials	Burcu Zeydan, MD Disclosure: Dr. Zeydan has nothing to disclose.
5:30 PM	376	Predictors of Vocational Status Among Persons with Multiple Sclerosis	Sarah Morrow, MD, MSC,FRCPC Disclosure: Dr. Morrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genzyme, Novartis, and Roche. Dr. Morrow has received research support from Novartis and Roche.
5:30 PM	377	Relevance of Age and Cerebrospinal Fluid Measures in Multiple Sclerosis associated with seizures	Shitiz Sriwastava, MBBS Disclosure: Dr. Sriwastava has nothing to disclose.
5:30 PM	378	Bone Microarchitecture and Bone Mineral Density in Multiple Sclerosis	Anna Olsson Disclosure: Dr. Olsson has received research support from has received support for congress participation from Teva and Merck.
5:30 PM	379	Impact of multiple comorbidities on EDSS at presentation in patients with multiple sclerosis: A cross-sectional study.	Faisal Alsallom, MD Disclosure: Dr. Alsallom has nothing to disclose.
5:30 PM	380	Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search	Vivek Khurana Disclosure: Dr. Khurana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Healthcare Private Limited.
5:30 PM	381	Erdheim-Chester Disease in the Brainstem Mimicking Tumefactive Demyelination.	Maria del Pilar Guillermo Prieto Eibl Disclosure: Dr. Prieto Eibl has nothing to disclose.
5:30 PM	382	Differential Expression of Alternative Splicing Variants in Individuals with Relapsing-Remitting Multiple Sclerosis	Michael Hecker, PhD Disclosure: Dr. Hecker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer HealthCare, Biogen, Novartis and Teva.
5:30 PM	383	Development of Multiple Sclerosis relapse flare after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1987-2017].	Moamina Fakhera Eddin Disclosure: Dr. Fakhera Eddin has nothing to disclose.
5:30 PM	384	EMPLOYMENT SITUATION IN BRAZILIAN PATIENTS DIAGNOSED WITH MULTIPLE SCLEROSIS	Denis Bichuetti, MD Disclosure: Dr. Bichuetti has received personal compensation for speaking/consulting from Bayer Health Care, Biogen Idec, Merck Serono, Genzyme-Sanofi, TEVA and Roche, and had travel expenses to scientific meetings sponsored by Bayer Health Care, Merck Serono, TEVA and Roche.
5:30 PM	385	Impact of Age on 30-day Readmission After Primary Admission for Multiple Sclerosis: A Nationwide Readmission Databse Analysis	Smit Patel Disclosure: Dr. Patel has nothing to disclose.
5:30 PM	386	The Prevalence and Special Characteristic of Multiple Sclerosis that Begins in Older Adults	Estefanía García Molina Disclosure: Dr. Valero López has nothing to disclose.
5:30 PM	387	Does Co-morbidity with Familial Mediterranean Fever change the course of Multiple Sclerosis?	Aksel Siva, MD Disclosure: Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Teva, Genzyme, Bayer, and Roche.
5:30 PM	388	Protective role of Multiple Sclerosis in Stroke; Analysis of a large national data base	Maryam Zulfiqar Disclosure: Dr. Zulfiqar has nothing to disclose.
5:30 PM	389	A Whole-Exome Sequencing Study In Multiple Sclerosis Multiplex Families	Elisabetta Mascia Disclosure: Dr. Mascia has nothing to disclose.
5:30 PM	390	The Saudi Arabian National Multiple Sclerosis Registry (NMSR): Initial Results Saudi MS Registry Study Group*	M. Al-Jumah, MD, MBBS Disclosure: Dr. Al-Jumah has nothing to disclose.
5:30 PM	391	Demyelination and Neurodegeneration along the Visual Pathway are more prominent in Secondary Progressive than Primary Progressive Multiple Sclerosis.	Simone Guerrieri Disclosure: Dr. Guerrieri has nothing to disclose.
5:30 PM	392	Regional thalamic volumes preferentially correlate with extra-thalamic white matter injury and clinical disability in multiple sclerosis subtypes	Kedar Mahajan, MD, PhD Disclosure: Dr. Mahajan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme.
5:30 PM	393	Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing-Remitting Multiple Sclerosis	Davorka Tomic Disclosure: Dr. Tomic is an employee of Novartis Pharma AG.
5:30 PM	394	Predicting Physical and Mental Disability in Patients with Multiple Sclerosis: a Longitudinal Analysis of Electronic Health Records.	Farren Briggs Disclosure: Dr. Briggs has nothing to disclose.
5:30 PM	395	New versus old: Implications of diagnostic criteria for Relapsing Remitting Multiple Sclerosis	Nuala McNicholas, MBBS Disclosure: Dr. McNicholas has nothing to disclose.
5:30 PM	396	Familial Multiple Sclerosis: An Epidemiological Study in Pontevedra, Spain.	Ana Rodriguez Regal Disclosure: Dr. Rodriguez Regal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen and TEVA.
5:30 PM	397	Increased Risk of Ischemic Stroke Associated with Untreated Multiple Sclerosis: A Nationwide Case-Control Population-Based Study.	Asad Ikram, MD, MBBS Disclosure: Dr. Ikram has nothing to disclose.
5:30 PM	398	The North American Registry for Care and Research in Multiple Sclerosis	Anne H. Cross, MD Disclosure: Dr. Cross has received personal compensation for activities with AbbVie, BAYER, Biogen, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Novartis, and Teva. Dr. Cross has received research support for Genentech/ Roche.
5:30 PM	399	Long-term disability outcomes in relapsing-remitting multiple sclerosis: A 10-year follow-up study	Jelena Drulovic Disclosure: Dr. Drulovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with advisory boards: Bayer Schering Pharma, merck Serono, Teva, Genzyme, a Sanofi Company, Merck Serono, teva, Bayer Schering, genzyme, a Sanofi Company, Medis, and Roche. Dr. Drulovic has received research support from research grant support: Ministry of Education and Science, and The Republic of Serbia (project no. 175031).
5:30 PM	400	Patient Perspectives on Discontinuing Disease Modifying Therapies in the NARCOMS Registry	Marisa McGinley, DO Disclosure: Dr. McGinley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme.
MS Animal Models
Start Time	Pub.	Title	Presenter
5:30 PM	401	Astrocyte Transciptomics in EAE Lead to Cholesterol Homeostasis as a New Treatment Target	Noriko Itoh Disclosure: Dr. Itoh has nothing to disclose.
5:30 PM	402	Longitudinal Diffusion Tensor Imaging in Theiler's Murine Encephalomyelitis Virus Driven Mouse Model of MS Reveals White Matter Change	Ely Cuberos Disclosure: Dr. Cuberos has nothing to disclose.
5:30 PM	403	Interaction of Normal and Antineuronal IgGs with Neurons in Rat Brain Slice Cultures: Comparison of IgG Uptake, Clearance, Intraneuronal Binding to Target Antigens, and Production of Neuronal Death	John Greenlee, MD, FAAN Disclosure: Dr. Greenlee has received personal compensation in an editorial capacity for Associate Editor for Medlink.
5:30 PM	404	Estrogen Receptor ? Ligand Acts on Two Pathways Within the CNS to Mediate Neuroprotection in the MS Model	Roy Kim Disclosure: Dr. Kim has nothing to disclose.
5:30 PM	405	Cellular Senescence Correlates with Demyelination, Brain Atrophy and Motor Impairment in a Model of Multiple Sclerosis	Maria Karamita Disclosure: Dr. Karamita has nothing to disclose.
5:30 PM	406	IL-11 antagonist suppresses Th17 cells-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis	Xin Zhang Disclosure: Dr. Zhang has nothing to disclose.
5:30 PM	407	IL-11-stimulated Encephalitogenic CD4+ Cells Induce Aggressive RREAE, Mediated via Th17, CD8+, CD19+ Cells and Neutrophils' Migration to CNS in Passive Transfer RREAE	Nazanin Kiapour Disclosure: Dr. Kiapour has nothing to disclose.
5:30 PM	408	Teriflunomide (Aubagio®) decreases microglial density in Theiler's Murine Encephalomyelitis Virus model of demyelination: Histological approach in combination with neuroimaging	Suyog Pol, PhD Disclosure: Dr. Pol has nothing to disclose.
5:30 PM	409	BDNF is necessary for neuronal activity-regulated oligodendrogenesis	Anna Geraghty Disclosure: Dr. Geraghty has nothing to disclose.
5:30 PM	410	Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T- and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice	Anna Schubart Disclosure: Dr. Schubart is and employee of Novartis.
5:30 PM	411	Complete Resolution of Clinical Signs and Synergism of the Combination Ponesimod-dimethyl Fumarate in Rat Models of Multiple Sclerosis	Laetitia Pouzol Disclosure: Dr. Pouzol has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion Pharmaceuticals Ltd.
5:30 PM	412	Cerebrospinal Fluid Derived from Primary Progressive MS Delays Remyelination after Lysolecithin-induced Demyelination	Nathan Kung Disclosure: Dr. Kung has nothing to disclose.
5:30 PM	413	Dietary Conjugated Linoleic Acid Supplementation Modulates CNS Autoimmunity	Ann-Katrin Fleck Disclosure: Dr. Fleck has nothing to disclose.
5:30 PM	414	Passive transfer of human aquaporin-4 IgG autoantibodies causes complement-independent spinal cord immunopathologies in mice	Koon Chan, MD, MBBS Disclosure: Dr. Chan has nothing to disclose.
MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy II
Start Time	Pub.	Title	Presenter
5:30 PM	415	Neurocognitive Correlates of Impaired Perceptual Decision-Making in MS and their Link to Quality of Life	Martin Weygandt, PhD Disclosure: Dr. Weygandt has nothing to disclose.
5:30 PM	416	Treatment satisfaction and illness perception in MS patients	Jarrett Leech Disclosure: Dr. Leech has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Onnit Labs, LLC. Dr. Leech has received compensation for serving on the Board of Directors of Onnit Labs, LLC.
5:30 PM	417	Pain Network and Neuropsychological Profile in Multiple Sclerosis and Migraine Patients	Claudio Gobbi, MD Disclosure: Dr. Gobbi has nothing to disclose.
5:30 PM	418	Neuroanatomical Correlates of Latent Variables Speed and Memory in Early Multiple Sclerosis	Ilena George, MD Disclosure: Dr. George has nothing to disclose.
5:30 PM	419	Exploring Cannabis use by Patients with Multiple Sclerosis in a state where Cannabis is legal	Laura J Weinkle Disclosure: Dr. Weinkle has nothing to disclose.
5:30 PM	420	Screening of cognitive impairment in patients with multiple sclerosis (MS): the BICAMS short version for patient-centered care in small neurological institutions	Iris-Katharina Penner Disclosure: Dr. Penner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adamas Pharma, Bayer Pharma, Biogen GmbH, Desitin, Genzyme, Merck Serono, Novartis Pharma GmbH, Roche, and Teva. Dr. Penner has received research support from Teva.
5:30 PM	421	A new electronic and brief neuropsychological scale to detect cognitive impairment (CI) in patients with multiple sclerosis (MS): Validation study of the MS-COG-e scale	José Meca Lallana Disclosure: Dr. Meca-Lallana has received consulting or speaking fees from Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva.
5:30 PM	422	Effects of Live-Online Education on Multiple Sclerosis Disease Management: Changes in Patient Experience, Clinical Practice, Provider Knowledge and Competence	Anne Roc, PhD Disclosure: Dr. Roc has nothing to disclose.
5:30 PM	423	Cognitive reserve is consistently related to cognitive performance in Multiple Sclerosis	Alvino Bisecco Disclosure: Dr. Bisecco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck.
5:30 PM	424	Impact of Multiple Sclerosis on Employment and its Association with Anxiety, Depression, Fatigue and Sleep Disorders	Edgar Carnero Contentti Disclosure: Dr. Carnero has nothing to disclose.
5:30 PM	425	NA	NA NA Disclosure:
5:30 PM	426	NA	NA NA Disclosure:
5:30 PM	427	NA	NA NA Disclosure:
5:30 PM	428	NA	NA NA Disclosure:
Neuropathy II
Start Time	Pub.	Title	Presenter
5:30 PM	429	Skin coldness and painful cold: the common symptom in patients with clinically suspected small fiber neuropathy in Korea	Eun Bin Cho, MD Disclosure: Dr. Cho has nothing to disclose.
5:30 PM	430	Is There A Relationship Between Exacerbated Diabetic Peripheral Neuropathy And Metformin?	Mohammed El-Sherif, MD Disclosure: Dr. El-Sherif has nothing to disclose.
5:30 PM	431	Brachial plexopathy after influenza vaccination in adults in the USA. A report from the CDC/FDA Vaccine Adverse Event Reporting System (1990-2017)	Shreya Shah Disclosure: Dr. Shah has nothing to disclose.
5:30 PM	432	Neuropathy with Dysarthria and Ophthalmoparesis	Tekalign Burka, MD Disclosure: Dr. Burka has nothing to disclose.
5:30 PM	433	Use of Intravenous Immunoglobulin in Small Fiber Neuropathy associated with FGFR3	Ajal Dave, MD Disclosure: Dr. Dave has nothing to disclose.
5:30 PM	434	Isolated external ophthalmoplegia associated with IgG anti-GQ1b antibody	Sunhee Kim, MD Disclosure: Dr. Kim has nothing to disclose.
5:30 PM	435	A case of remission from multifocal motor neuropathy following rituximab	Natalia Gonzalez, MD Disclosure: Dr. Gonzalez has nothing to disclose.
5:30 PM	436	Late Onset TTR-related Familial Amyloid Polyneuropathy (FAP) in Two Patients with Acquired Demyelinating Features	Nazila Rad, MD Disclosure: Dr. Rad has nothing to disclose.
5:30 PM	437	A Novel Report of Nivolumab-Induced Parsonage-Turner Syndrome Associated with Hourglass-like Constriction of the Anterior Interosseous Nerve	Michael Porambo Disclosure: Dr. Porambo has nothing to disclose.
5:30 PM	438	Acute Intermittent Porphyria: Sometimes DIfficult to Diagnose	Yuri Macedo, MD Disclosure: Dr. Macedo has nothing to disclose.
5:30 PM	439	Ganglioside Antibodies in Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) and its Variants	Mithila Fadia, MBBS Disclosure: Dr. Fadia has nothing to disclose.
5:30 PM	440	Cognitive Biases at Bedside Resulting in Diagnostic Error of Guillain-Barré Syndrome	Rohit Gummi Disclosure: Dr. Gummi has nothing to disclose.
5:30 PM	441	Heterozygous Mutations of SH3TC2 as a Cause of HNPP	Devin Prior, MD Disclosure: Dr. Prior has nothing to disclose.
5:30 PM	442	Reduction in Idiopathic Peripheral Neuropathy Diagnoses Using a Comprehensive EMR-based Laboratory Order Set	Fang Bai, MD Disclosure: Dr. Bai has nothing to disclose.
5:30 PM	443	Brachial Plexopathy Post Transcatheter Arterial Chemoembolization	Kavneet Kaur, MD Disclosure: Dr. Kaur has nothing to disclose.
5:30 PM	444	Novel Mutation in KIF5A Causing Hereditary Spastic Paraplegia with Axonal Sensorimotor Neuropathy	Mathieu Cuchanski, DO Disclosure: Dr. Cuchanski has nothing to disclose.
5:30 PM	445	Eosinophilic Vasculitic Neuropathy As A Presentation Of Churg-Strauss Syndrome	Sandeep Devarapalli, MD Disclosure: Dr. Devarapalli has nothing to disclose.
5:30 PM	446	Outcome comparison of mechanically ventilated Guillain-Barre Syndrome versus Myasthenia Gravis in US Hospitals	Anantha Vellipuram Disclosure: Dr. Vellipuram has nothing to disclose.
5:30 PM	447	Guillain-Barre Syndrome as a Rare Initial Presentation of Systemic Lupus Erythematosus.	Swathy Chandrashekhar, MD Disclosure: Dr. Chandrashekhar has nothing to disclose.
5:30 PM	448	Rapidly Progressive POEMS Syndrome with Absent M protein in Serum or Urine, Normal Bone Survey, and Normal Non-targeted Bone Marrow Biopsy	Payam Soltanzadeh, MD Disclosure: Dr. Soltanzadeh has nothing to disclose.
5:30 PM	449	Modifying Hyperglycemic Peripheral Nerve Injury	Mark Stecker, MD Disclosure: Dr. Stecker has received royalty, license fees, or contractual rights payments from UPTODate.
5:30 PM	450	Rare Case of Ulnar Neuropathy	Anai Hamasaki, MD Disclosure: Dr. Hamasaki has nothing to disclose.
5:30 PM	451	Ustekinumab related CIDP in a patient with psoriatic arthritis	Gamaleldin Osman, MD Disclosure: Dr. Osman has nothing to disclose.
5:30 PM	452	Proximal Motor Sensory Hereditary Neuropathy (HMSN-P) in a Peruvian Family with Japanese Ancestry	Elison Sarapura-Castro, MD Disclosure: Dr. Sarapura Castro has nothing to disclose.
5:30 PM	453	Acute Motor Axonal Neuropathy (AMAN) presenting with truncal and appendicular ataxia	Ashmanie Mahatoo, MD Disclosure: Dr. Mahatoo has nothing to disclose.
Neuromuscular Diagnostics, Genetics, and Biomarkers
Start Time	Pub.	Title	Presenter
5:30 PM	454	Needle Impedance-Electromyography (I-EMG): a New Technique for the Electrodiagnostic Laboratory	Seward Rutkove, MD Disclosure: Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, and Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc.. Dr. Rutkove holds stock and/or stock options in Myolex, Inc.. Dr. Rutkove has received research support from Flex-Pharma, Inc..
5:30 PM	455	Feasibility and Validation of Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis	Marie Wencel, CCRP Disclosure: Dr. Wencel has nothing to disclose.
5:30 PM	456	A New Method to Detect Potential Causative Genes for Spastic Paraplegia Utilizing Aggregate Data of Whole Exome Sequencing	Masaki Tanaka Disclosure: Dr. Tanaka has nothing to disclose.
5:30 PM	457	Smart Somatotopic Quantitative Sensory Testing findings in hATTR with Polyneuropathy	Marcus Vinicius Pinto Disclosure: Dr. Pinto has nothing to disclose.
5:30 PM	458	Genetics in patients with hereditary neuropathy	Ernesto Alonso-Labori, MD Disclosure: Dr. Alonso-Labori has nothing to disclose.
5:30 PM	459	Correlation of supranormal sensory nerve action potential amplitudes (supraSNAPs) with sensory nerve "hyperexcitable" symptoms	Philip Tipton, MD Disclosure: Dr. Tipton has nothing to disclose.
5:30 PM	460	The Role of Needle Electromyography in the Evaluation of Carpal Tunnel Syndrome	Cory Kogelschatz, MD Disclosure: Dr. Kogelschatz has nothing to disclose.
5:30 PM	461	Morphometry of dorsal rootlets using immunofluorescent confocal microscopy	Adam Loavenbruck, MD Disclosure: Dr. Loavenbruck has nothing to disclose.
5:30 PM	462	Utility of Neuromuscular Ultrasound in the Evaluation of Proximal Median Neuropathies: A Case Series	Elina Zakin Disclosure: Dr. Zakin has nothing to disclose.
5:30 PM	463	Why do we repeat electrodiagnostic studies? And, does it make a difference?	Shivakrishna Kovi Disclosure: Dr. Kovi has nothing to disclose.
5:30 PM	464	Ultrasound Guided Open Muscle Biopsy	Shumaila Sultan, MD Disclosure: Dr. Sultan has nothing to disclose.
5:30 PM	465	Clinic and Lab Based Respiratory Testing in Patients with Myasthenia Gravis	Hans Katzberg, MD Disclosure: Dr. Katzberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring and Octapharma. Dr. Katzberg has received research support from Octapharma.
5:30 PM	466	Comparison of Train of Four with Repetitive Nerve Stimulation in the ICU	Omer Suhaib, MD, MBBS Disclosure: Dr. Suhaib has nothing to disclose.
5:30 PM	467	Should We Refer Patients with Pain for Electromyography?	Shivkumar Bhadola Disclosure: Dr. Bhadola has nothing to disclose.
Medical Student Essay Award Recipients
Start Time	Pub.	Title	Presenter
5:30 PM	468	Functional neurological disorders in Parkinson disease	Benjamin Wissel Disclosure:
5:30 PM	469	Ghost in the Machine: Historical Aspects of Irreversible Brain Injury and Brain Death	Yi Tong Disclosure: Dr. Tong has nothing to disclose.
5:30 PM	470	Discovery of novel recessive genes in a consanguineous cohort using genotype-phenotype correlations	Kristen Martin Disclosure: Dr Martin has nothing to disclose.

Ready to register for the 2018 AAN Annual Meeting?

Related Courses

Saturday April 21, 2018
7:00 AM-9:00 AM
C1	Mild Cognitive Impairment: Implications for Clinicians	Ronald Petersen PhD, MD, FAAN
C3	Emergency Room Neuro-ophthalmology	Heather Moss MD, PhD, FAAN
C4	Hyperkinetic Movement Disorders: Videodiagnosis and Treatment	Steven Frucht MD
7:00 AM-12:30 PM
C5	Clerkship and Program Directors Conference: Demonstrating Your Impact as a Medical Educator	Joseph Safdieh MD, FAAN
7:30 AM-8:15 AM
	Are You My Mentor? How to Select a Good Mentor for Your Research Career	Deborah Hall MD, PhD, FAAN
8:15 AM-9:00 AM
	How Educating Can Improve Productivity During Clinical Activities	Veronica Santini MD
8:25 AM-9:10 AM
	Work Life Balance in Research	Amanda Peltier MD, MS
9:20 AM-9:50 AM
	How to Successfully Publish Quality Improvement Projects	Anup Patel MD, FAAN, Rohit Das MD, FAAN
9:30 AM-11:30 AM
C9	Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies	Amanda Peltier MD, MS
C11	Treatment of Pediatric Multiple Sclerosis in the Current Era	Brenda Banwell MD, FAAN
C13	Neuroimaging Biomarkers Across the Dementia Spectrum	Liana Apostolova MD, FAAN
C14	Parkinson's Disease Update	Melissa Nirenberg MD, PhD, FAAN
C10	More than Medicine: How to Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease	Farrah Daly MD, MBA
10:00 AM-10:50 AM
	Investigator Panel: How I Launched My Career with NIH Funding, Private Funding, AAN Research Program Funding and/or Government Funding	An Hong Do MD, Nicoline Schiess MD, Daniel Claassen MD
10:15 AM-10:45 AM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
11:30 AM-12:00 PM
	Office Hours: Research Careers in Industry	Brandy Matthews MD, FAAN
12:00 PM-4:00 PM
C15	Resident Basic Science I: Neuropharmacology	James Owens MD, PhD
C17	Neurophysiologic Intraoperative Monitoring Skills Workshop (Registration Required)	Aatif Husain MD
12:15 PM-1:00 PM
	What I Learned About Research - An Early Career Perspective	Logan Schneider MD
12:20 PM-12:50 PM
	How to Find Training: The Best Clinical Research and Methodology Training Options	Karen Johnston MD, MSC, Nicole Chiota-McCollum MD
12:45 PM-1:45 PM
	Ask Us Anything: Expert Panel on Headache and Facial Pain	Deborah Friedman MD, MPH, FAAN, Lawrence Newman MD, FAAN, Peter Goadsby MD, PhD
1:30 PM-3:30 PM
C19	Pediatric Neuro-ophthalmology Update	Christopher Glisson DO
C21	Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia	Amanda Peltier MD, MS
C22	Stroke in Young Adults and Women	Aneesh Singhal MD, FAAN
C20	The Neurology of Social Behavior	Bradford Dickerson MD
C24	Diagnosis and Treatment of Functional Movement Disorders	Mark Hallett MD, FAAN
1:40 PM-2:10 PM
	Clinical Trials Methodology Course - Information Session with William Meurer MD, MS, CTMC Principal Investigator	William Meurer MD
3:30 PM-4:00 PM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
4:15 PM-5:30 PM
PL1	Hot Topics Plenary Session

Sunday April 22, 2018
7:00 AM-9:00 AM
C25	Hot Topics and Controversies in Parkinson's Disease	Melissa Nirenberg MD, PhD, FAAN
C26	Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema	Nancy Newman MD, FAAN
C28	Autism Spectrum Disorders What We Know and Where We Are Going	Rujuta Wilson MD
C29	Faculty Development: Enhancing Your Role in Student and Resident Training	Vicki Shanker MD
C31	Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies	Michael Shy MD
C32	Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates	Ellen Bubrick MD
C33	Clinicopathological Correlation Session in Dementia	David Irwin MD
C34	Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making	Aaron Miller MD, FAAN
C30	Controversies in Stroke Treatment and Prevention	Steven Messe MD, FAAN, FAHA
7:45 AM-8:15 AM
	Research in Residency: How to Choose the Right Project	Roy Strowd MD
8:00 AM-9:00 AM
S1	"Best of" Session: Cerebrovascular Disease and Interventional Neurology
8:15 AM-9:00 AM
	K is for Career Development: Tips From Successful Applications for NIH Career Development Awards	Logan Schneider MD
9:15 AM-12:00 PM
PL2	Presidential Plenary Session
9:30 AM-10:00 AM
	Collaboration Corner: Medical Student Office Hours	Rana Said MD
10:15 AM-10:45 AM
	Collaboration Corner: Program Coordinators: Interpreting ACGME Resident and Faculty Survey to Improve Responses	Tammi Miller C-TAGME
11:00 AM-11:45 AM
	Colloboration Corner: Faculty Development and the Role of Program Coordinator	Mary Phelan BS, C-TAGME
11:30 AM-5:30 PM
P1	Poster Session I
12:00 PM-12:45 PM
	How to Promote Healthy Cognitive Aging: What Should We Tell Our Patients and Ourselves?	Kirk Daffner MD, FAAN
12:00 PM-12:50 PM
PD1	Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session
12:30 PM-1:00 PM
	Office Hours: Surviving as a Clinician Researcher	Lisa Silbert MD, FAAN
1:00 PM-1:30 PM
	Being a Great Chief Resident	Roy Strowd MD
1:00 PM-2:00 PM
	The M3D Lab: 3d Printing, VR and AR in Medicine	Korak Sarkar MD
1:00 PM-3:00 PM
C37	Nonmotor Manifestations of Parkinson's Disease I	Charles Adler MD, PhD, FAAN
C41	Peripheral Neuropathy II: Diabetic and Inherited Neuropathies	Michael Shy MD
C42	Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases	Joseph Sirven MD, FAAN
C43	Developing the Treatments of Tomorrow I: Taking Molecules from Lab to Man	Amy Brooks-Kayal MD, FAAN
C44	Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria	Nancy Newman MD, FAAN
S2	Clinical Trials and Therapeutic Approaches in Neurodegenerative Diseases
S3	Movement Disorders: Parkinson's Disease: Genetics, Biomarkers, and Diagnosis
S6	MS Neuroimaging
1:00 PM-5:30 PM
C49	Neuromuscular Ultrasound Skills Workshop (Registration Required)	Craig Zaidman MD
C47	Resident Basic Science II: Neuropathology	Matthew Cykowski MD
1:20 PM-1:50 PM
	So You Have a Research Idea - How Do You Turn it into a Project?	Edward Bertram MD, FAAN
1:30 PM-2:30 PM
	Hall of Presidents: Using Past Experience to Solve the Futures Problems	Ralph Sacco MD, MS, FAHA, FAAN, Thomas Swift MD, FAAN, Sandra Olson MD, FAAN, Terrence Cascino MD, FAAN, Robert Griggs MD, FAAN, Francis Kittredge MD,FAAN, Roger Rosenberg MD, FAAN, Stanley Fahn MD, FAAN, Stephen Sergay MB BCh, FAAN
1:45 PM-2:15 PM
	Career Stories: Challenges for the Physician Scientist	Mark Hallett MD, FAAN
2:00 PM-2:30 PM
	Breaking Down Silos: Using Simulation for Interprofessional Team Education to Enhance Clinical Outcomes in Neurology	Tracey Milligan MD, FAAN, Barbara Dworetzky MD, FAAN
2:30 PM-3:00 PM
	Innovations for Multiple Sclerosis Monitoring and Care	Tanuja Chitnis MD, FAAN
	Neuro-ophthalmology: A Career with Multiple Opportunities	Wayne Cornblath MD, FAAN, Eric Eggenberger DO, FAAN
3:00 PM-3:30 PM
	The Power of Art, Interior Design and Bibliotherapy in Parkinson’s and Cognition	Elizabeth Barber PhD
3:30 PM-4:00 PM
	Hand in Hand with Art and Advocacy	Daniel Potts MD, FAAN
3:30 PM-4:30 PM
S7	Pain and Palliative Care
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
3:30 PM-5:30 PM
N1	Neuroscience in the Clinic: Autism Myth Busters	Shafali Jeste MD, Sarah Spence MD,PhD
C52	Nonmotor Manifestations of Parkinson's Disease II	Charles Adler MD, PhD, FAAN
C56	Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing	Michael Shy MD
C57	Developing the Treatments of Tomorrow II: Clinical Trials in Neurology	Jeffrey Gelfand MD, MAS, FAAN
C58	Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus	Nancy Newman MD, FAAN
C59	Actualización Sobre el Tratamiento de la Esclerosis Múltiple	Lilyana Amezcua MD
S8	Progressive MS Therapies and Age-Dependent Factors in MS Therapy
S9	Epilepsy/Clinical Neurophysiology (EEG) I
S10	Intracerebral and Subarachnoid Hemorrhage
4:00 PM-4:30 PM
	Transitioning from Private Practice to Academics	Neil Busis MD, FAAN
4:15 PM-5:00 PM
	Introduction to the Fascinating World of Movement Disorders	Shilpa Chitnis MD, PhD, FAAN, FANA, Svjetlana Miocinovic MD, PhD
4:30 PM-5:00 PM
	How to Start a Career in Clinical Trials	Aleksandar Videnovic MD, MSc, FAAN
4:30 PM-5:30 PM
	What is that Twitch?	Leonard Verhagen Metman MD, PhD, Susan Bressman MD, FAAN
4:45 PM-5:15 PM
	Everything You Wanted to Know About the R&F Section of Neurology	Roy Strowd MD, John Millichap MD
5:00 PM-5:30 PM
	Statistics and Study Design: Pearls and Pitfalls	Senan Ebrahim
	Collaboration Corner: Introduction to the Fascinating World of Movement Disorders	Shilpa Chitnis MD, PhD, FAAN, FANA, Svjetlana Miocinovic MD, PhD
5:30 PM-6:00 PM
	Continuing the Conversation from C58: Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus	Nancy Newman MD, FAAN

Monday April 23, 2018
7:00 AM-9:00 AM
C62	Neuro-ophthalmology: Overview and Update	Nancy Newman MD, FAAN
C63	Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis	Michael Weiss MD, FAAN
C64	Child Neurology I: Pediatric Stroke, MS/Autoimmune	Marc Patterson MD, FAAN, FRACP
C66	Update on Medical Management of Stroke	Natalia Rost MD, MPH, FAAN, FAHA
C68	Cognitive Impairment Due to Alzheimer's Disease: Using Old Skills and New Tools for Diagnosis and Treatment	David Knopman MD, FAAN
C67	Video EEG: Name That Spell	Amy Crepeau MD
C60	Balance and Gait Disorders	Alfonso Fasano MD, PhD
7:30 AM-8:00 AM
	Defining and Managing Your Message as An Early Career Researcher	Corey Fehnel MD
7:45 AM-8:15 AM
	Using the R&F Section of Neurology for your Residents and Residency	Roy Strowd MD, John Millichap MD
8:00 AM-9:00 AM
S11	"Best of" Session: Epilepsy/Clinical Neurophysiology (EEG)
8:15 AM-9:00 AM
	Choosing An Academic Career in Neurology: Perspectives for Early Career Investigators and Foreign Medical Graduates	Deepak Gupta MBBS, Ciro Ramos Estebanez MD
9:15 AM-9:45 AM
	Collaboration Corner: Program Coordinators: Curriculum Building 101	Crys Draconi
9:15 AM-11:30 AM
PL3	Contemporary Clinical Issues Plenary Session
10:15 AM-11:00 AM
	Collaboration Corner: Program Coordinator Best Practices for Recruitment Season	Tammi Miller C-TAGME, Peggy Nolty
11:30 AM-12:00 PM
	Child Neurology - Staying on Track	Warren Lo MD
11:30 AM-7:00 PM
11:45 AM-12:30 PM
	Finding Your Niche in Neurology: Perspectives from an Epileptologist and Educator	Chad Carlson MD
11:45 AM-12:35 PM
PD2	Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session
12:00 PM-12:30 PM
	Office Hours: Working with an Epidemiologist	Kelly Sullivan PhD
	Collaboration Corner: Child Neurology - Staying on Track	Warren Lo MD
12:25 PM-1:45 PM
	Perception Is Reality: Are Neurologists Helping Patients Live Well with Dementia?	Daniel Potts MD, FAAN, Neelum Aggarwal MD
12:30 PM-1:00 PM
	Effectively Incorporating Telehealth into Clinical Research	Christopher Tarolli MD
12:45 PM-1:15 PM
	Collaboration Corner: Mejora Tu Desempeño Como Educador Médico	Yazmin Odia MD
12:45 PM-1:30 PM
	Transitioning From a Clinical Research Career to an Educational and Clinical Focused Career	Chad Carlson MD
1:00 PM-1:30 PM
	Subspecialty Sessions: IOM and cEEG	Eva Ritzl MD, FAAN
1:00 PM-2:15 PM
S12	Autonomic Disorders
1:00 PM-3:00 PM
C78	Therapeutic Temperature Modulation in the ICU	Stephan Mayer MD
C70	Evaluating Tremor in the Office	Vicki Shanker MD
C73	Child Neurology II: Epilepsy and Neuromuscular	Marc Patterson MD, FAAN, FRACP
C74	Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I	Jeffrey Gelfand MD, MAS, FAAN
C75	Safe and Appropriate Opioid Prescribing in Neurology	Shaheen Lakhan MD, PhD, MEd, FAAN
C76	Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging and Genetic Testing	Tahseen Mozaffar MD, FAAN
C80	Present and Future Biomarkers in Dementia: A Case-based Approach	Jonathan Graff-Radford MD
C77	Epilepsy Surgery Update	Stephan Schuele MD, FAAN
S13	Neuromyelitis Optica Spectrum Disorder and other Autoimmune Disorders
S14	Education and Patient Outcomes Research
S15	Cerebrovascular Disease Epidemiology and Outcomes
S16	Neuro-Ophthalmology/Neuro-Otology
1:00 PM-5:30 PM
C82	Resident Basic Science III: Neuroanatomy: All the Lesions	Zachary London MD, FAAN
C83	Neuro-ophthalmology and Neurovestibular Exam Lab Skills Workshop (Registration Required)	John Pula MD, FAAN
1:30 PM-2:00 PM
	American Brain Foundation Neuroscience Crowdfunding Site	Eugene Scharf MD
1:30 PM-2:15 PM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
2:00 PM-2:45 PM
	Physical Exercise and Cognitive Training in Neurology: Application in Aging and Neurodegenerative Disease	Ergun Uc MD
2:20 PM-2:50 PM
	Why Study the History of Neurology?—A Panel Discussion Featuring the Lawrence C. McHenry Award and Roland P. Mackay Medical Student Essay Award Winners	Yi Tong , Bart TH Lutters , Christopher Boes MD, FAAN
2:30 PM-3:00 PM
	Office Hours: Defining and Managing Your Message As An Early Career Scientist	Christopher Anderson MD,PhD
	Writing & Reviewing for the R&F Section of Neurology	John Millichap MD
	Writing & Reviewing for the R&F Section of Neurology	Roy Strowd MD, John Millichap MD
2:45 PM-3:30 PM
	Up Your Game as a Medical Educator in Neurology	Rachel Marie Salas MD, FAAN
3:00 PM-3:30 PM
	Continuing the Conversation from C70: Evaluating Tremor in the Office	Vicki Shanker MD
3:30 PM-5:30 PM
N2	Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy	John Day MD, PhD, Richard Finkel MD
C86	Child Neurology III: Headache, TBI/Post-concussion	Marc Patterson MD, FAAN, FRACP
C87	Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II	Jeffrey Gelfand MD, MAS, FAAN
C88	Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids	James Watson MD
C89	Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology	Tahseen Mozaffar MD, FAAN
C91	Chronic Traumatic Encephalopathy: Update	Andrew Budson MD
C95	Actualización Sobre las Infecciones del Sistema Nervioso Central y la Medicina Tropical	Oscar Del Brutto MD, FAAN
C94	Hot Topics in Stroke Education and Practice	Pierre Fayad MD, FAAN, FAHA
S18	Movement Disorders: Ataxia and Tremor
S19	Epilepsy/Clinical Neurophysiology (EEG) II
3:45 PM-4:30 PM
	Teaching Communication Skills: From Good to Great	Tara Cook MD
4:00 PM-4:30 PM
	Oportunidades de Entrenamiento Clínico en los Estados Unidos para Médicos Graduados en el Extranjero	Leticia Tornes MD, Camilo Gutierrez MD
	Panel Discussion with the 2018 John Dystel Prize for Multiple Sclerosis Research Award Recipient	Nancy Sicotte MD, FAAN, Frederik Barkhof
4:30 PM-5:00 PM
	Collaboration Corner: Teaching Communication Skills: From Good to Great	Tara Cook MD
4:45 PM-5:15 PM
	Residents and Fellows Office Hours	Sahil Gupta MD, Abhimanyu Mahajan MD
5:15 PM-6:15 PM
	Practicing Neurology in the 1960's and 1970's	Martin Samuels MD, MACP, FAAN, Thomas Swift MD, FAAN, Austin Sumner MD, FAAN, Sandra Olson MD, FAAN

Tuesday April 24, 2018
7:00 AM-9:00 AM
C96	Status Epilepticus	Stephan Schuele MD, FAAN
C97	Vascular Cognitive Impairment and Dementia: Current Status and Future	Larry Goldstein MD, FAAN, FAHA
C98	Multiple Sclerosis Overview I: Clinical Pearls	John Corboy MD, FAAN
C102	Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson's Disease	Irene Litvan MD, FAAN
C103	Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings	Wayne Cornblath MD, FAAN
8:00 AM-8:30 AM
	Welcome to NINDS Day/Overview of NIH Funding With NINDS Director and NINDS Deputy Director	Walter Koroshetz MD, FAAN, Nina Schor MD, PhD, FAAN
8:30 AM-9:00 AM
	Office Hours: The Researcher Pipeline: The Benefits of Participating in Academic Medicine, Research and Clinical Trials as a Medical Student or Resident	Laurie Gutmann MD, FAAN
8:40 AM-9:10 AM
	K Awards and Training Programs	Adam Hartman MD, Nina Schor MD, PhD, FAAN
9:15 AM-11:30 AM
PL4	Clinical Trials Plenary Session
10:15 AM-10:45 AM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
11:30 AM-12:00 PM
	Reviewer to Editorial Board to Editor	Mark Hallett MD, FAAN
	Clinical Decision Support for Ordering of Diagnostic Imaging	David Evans MBA
11:30 AM-7:00 PM
P3	Poster Session III
11:45 AM-12:35 PM
PD3	Aging and Dementia Poster Discussion Session
12:00 PM-12:30 PM
	Office Hours: How to Get a K-Award	Michael Levy MD, FAAN
12:00 PM-12:45 PM
	Treatment of Neuropathy Symptoms Without Medication	Janice Wiesman MD, FAAN
	Collaboration Corner: Medical Student Office Hours	Justin Jordan MD, MPH
12:30 PM-1:00 PM
	Office Hours: Bridge Funding	Randolph Marshall MD, FAAN
12:40 PM-1:10 PM
	NIH Funding and Professional Development Opportunities for Diverse Researchers	Michelle Jones-London PhD
1:00 PM-1:30 PM
	Subspecialty Sessions: IOM and cEEG	Eva Ritzl MD, FAAN
	Office Hours: VA Research Funding: Career Development Awards	Beth Leeman-Markowski MD, MA
1:00 PM-1:45 PM
	Complementary Therapies in Parkinson's Disease	Veronica Santini MD
1:00 PM-3:00 PM
N3	Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology	Guy Rouleau MD, PhD, Massimo Pandolfo MD, FAAN
C106	Critical Care EEG Monitoring	Suzette LaRoche MD, FAAN
C107	What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders	Daniel Kaufer MD, FAAN
C109	Multiple Sclerosis Overview II: Clinical Advances	Scott Newsome DO, FAAN
C110	Neurologic Complications in Adults with Down Syndrome	Andrea Gropman MD
C111	Enhancing Your Career and Practice Through Neuropalliative Care	Maisha Robinson MD, MS
C115	Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia	John Morgan MD, PhD
C116	Cerebrovascular Disease I: Prevention	Larry Goldstein MD, FAAN, FAHA
C117	Introduction to Clinical Research and Methods	Deborah Hall MD, PhD, FAAN
S21	Revascularization in Acute Ischemic Stroke
S22	Advances in Muscular Dystrophy and Congenital Myopathy
PL10	Invited Science: Movement Disorders
1:00 PM-5:30 PM
C119	EMG Skills Workshop: Basic (Registration Required)	Ezgi Tiryaki MD, FAAN
1:20 PM-1:50 PM
	NIH Grant Review Process	Adam Hartman MD, Michael Oshinsky PhD
1:30 PM-2:00 PM
	Office Hours: Clinical Research Recommendations for Residents and Fellows	Benjamin Tolchin MD
	Liftware Suite of Assistive Devices: Putting the User First	William Marks MD, FAAN
1:30 PM-2:15 PM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
1:45 PM-2:15 PM
	Academic Career Panel: Find out How to Get Your Career Started	Joseph Safdieh MD, FAAN, Jennifer Molano MD, FAAN
2:00 PM-2:30 PM
	NINDS Clinical Trials (new NIH definition) and networks, NeuroNEXT, StrokeNET, SIREN	Clinton Wright MD
2:00 PM-2:45 PM
	Dancing with Parkinson's	Diviya Kaul MD
2:30 PM-3:00 PM
	How to Start a Career in Neurology Education	Joseph Safdieh MD, FAAN
	The Why and How of Getting a Billion Dollar EHR to Make Their System Work Better for Neurologists	Allison Weathers MD, FAAN
2:40 PM-3:10 PM
	Pain Research Funding Opportunities, Clinical and Basic	Clinton Wright MD, Michael Oshinsky PhD
3:15 PM-3:45 PM
	Staying on Track: A Career as a Clinical Researcher	Rebecca Gottesman MD
3:30 PM-4:00 PM
	Quantitative Gait Analysis in Neurologic Conditions: Neurodevelopmental Disorders as a Case Example	Rujuta Wilson MD
3:30 PM-5:30 PM
C120	Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome	Ligia Onofrei MD
C130	Disorders of Motor Programming: The Apraxias and Action-Intentional Disorders Chalk Talk	Kenneth Heilman MD, FAAN
C122	Multiple Sclerosis Overview III: The Pathogenesis of Multiple Sclerosis and Mechanism of Action of Treatments for MS	Olaf Stuve MD, PhD, FAAN
C123	Child Neurology: A Case-based Approach	Elaine Wirrell MD, FAAN
C124	The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders	Tobias Walbert MD, PhD
C128	Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics	John Morgan MD, PhD
C129	Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke	Philip Gorelick MD, MPH, FAAN
S24	MS Outcome Measures and Biomarkers
S25	Advances in Amyotrophic Lateral Sclerosis
S26	Movement Disorders: Parkinson's Disease Clinical Trials
4:00 PM-4:30 PM
	Your Grant Proposal Was Rejected: Now What? Turning a Feedback Into a Successful Project	Amy Brooks-Kayal MD, FAAN
4:45 PM-5:15 PM
	Residents and Fellows Office Hours	Sahil Gupta MD, Abhimanyu Mahajan MD

Wednesday April 25, 2018
7:00 AM-9:00 AM
C140	Paroxysmal Movement Disorders	Kailash Bhatia MD, FAAN
C138	Clinical EEG I: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading	Selim Benbadis MD, FAAN
C135	Neurocognitive Assessment for Neurologists	Mario Mendez MD, PhD, FAAN
C136	Multiple Sclerosis Therapy: Disease-modifying Treatment I	Scott Newsome DO, FAAN
C141	Integrating Sleep Medicine Concepts into Your Child Neurology Practice	Suresh Kotagal MD, FAAN
C142	Mastering EMG Waveform Recognition Skills in Just Two Hours!	Devon Rubin MD, FAAN
C133	Higher Cortical Visual Disorders: Case-based Review	Sashank Prasad MD
C143	Evaluation and Treatment of Common Spine Disorders	J. D. Bartleson MD, FAAN
8:00 AM-8:45 AM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
8:00 AM-9:00 AM
S27	"Best of" Session: Movement Disorders
8:00 AM-9:10 AM
	How to Write and Publish Research Papers, Reviews and Other Scientific Communications	Mark Hallett MD, FAAN, Francois Boller MD, PhD, FAAN, Michael Aminoff MD, DSc, FAAN
8:15 AM-9:00 AM
	How to Give Effective Feedback	Laurice Yang MD, MHA, Veronica Santini MD
8:30 AM-9:00 AM
	Office Hours: Selecting an AAN Research Program Mentor	Brian Edlow MD
9:15 AM-9:45 AM
	RITE® (Residency In-service Training Examination) Office Hours	James Owens MD, PhD, Raymond Price MD
9:15 AM-11:30 AM
PL5	Frontiers in Neuroscience Plenary Session
10:45 AM-11:15 AM
	Residents and Fellows Office Hours	Abhimanyu Mahajan MD
10:45 AM-11:30 AM
	Collaboration Corner: Student Interest Group in Neurology (SIGN) Office Hours	Raghav Govindarajan MD, FAAN
11:30 AM-7:00 PM
P4	Poster Session IV
11:45 AM-12:30 PM
	Collaboration Corner: Department Chair Office Hours	Larry Goldstein MD, FAAN, FAHA
11:45 AM-12:35 PM
PD4	Cerebrovascular Disease and Interventional Neurology Poster Discussion Session
12:00 PM-12:30 PM
	Office Hours: Recruiting Difficult and Underrepresented Populations in Research	Jessica Robinson Papp MD, FAAN
	Utilizing Wearable Technology to Improve Neurological Care	Anup Patel MD, FAAN
12:45 PM-1:30 PM
	Clinical Research in the Area of Practice, Quality and Patient Safety	Mona Bahouth MD, Justin Jordan MD, MPH
1:00 PM-3:00 PM
C156	Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults	Katherine Noe MD, PhD, FAAN
C145	Severe TBI: From ICU to Rehabilitation	Susanne Muehlschlegel MD, MPH
C146	Non-Alzheimer's Dementia I: Frontotemporal Dementias	Gil Rabinovici MD
C147	Multiple Sclerosis Therapy: Disease-modifying Treatment II	John Rose MD, FAAN
C151	Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke	Philip Gorelick MD, MPH, FAAN
C152	Nystagmus and Saccadic Intrusions Made Simple	Janet Rucker MD
C155	Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System	Christopher Gibbons MD, FAAN
C150	Where is the Lesion? A History of Neurological Investigations Part I	Stefano Sandrone PhD
S29	Child Neurology and Developmental Neurology I
S30	Movement Disorders: Dystonia, Chorea, and other Disorders
S31	Therapeutics, Phenotypes, and Biomarkers in Neuromuscular Disorders
1:00 PM-5:30 PM
C159	Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop (Registration Required)	Diego Torres-Russotto MD, FAAN
1:20 PM-1:50 PM
	Community Education in Minority Population	Olajide Williams MD
1:30 PM-2:00 PM
	Acupuncture FAQ	Jennifer Bickel MD, FAAN
1:30 PM-2:15 PM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
1:30 PM-2:30 PM
	Parkinson Disease: Raising Your Game	Janis Miyasaki MD, FAAN, Cynthia Comella MD, FAAN, Oksana Suchowersky MD, FAAN
1:45 PM-2:30 PM
	Otoneurology, a Subspecialty Looking to Grow	Marcello Cherchi MD, PhD, FAAN
2:00 PM-2:30 PM
	Office Hours: Comparative Effectiveness Research in Neurology	Lidia Maria Moura MD
2:30 PM-3:00 PM
	The Importance of Social Media in a Non-Insurance Based Practice	Peter McAllister MD
3:00 PM-3:30 PM
	Office Hours: Research Careers in Industry	Brandy Matthews MD, FAAN
3:15 PM-3:45 PM
	Training in Neurology While on a Visa: Challenges and Possible Solutions for Foreign Medical Graduates	Ahmed Obeidat MD, PhD
3:30 PM-5:30 PM
N4	Neuroscience in the Clinic: Opioid Use and Abuse: The Overlapping Neurobiology of Pain and Addiction, and the Path Toward Better Treatments	Jessica Robinson Papp MD, FAAN, Walter Koroshetz MD, FAAN
C170	Clinical EEG III: Neonatal and Pediatric	Nicholas Abend MD
C161	Non-Alzheimer's Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias	Gil Rabinovici MD
C162	Multiple Sclerosis Therapy: Symptom Management	Jonathan Carter MD
C165	Where is the Lesion? A History of Neurological Investigation Part II	Stefano Sandrone PhD
C166	Cerebrovascular Disease IV: Telestroke	Eric Anderson MD, PhD
C167	Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia	Janet Rucker MD
C169	Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System	Christopher Gibbons MD, FAAN
C171	Actualización Sobre Opciones Terapéuticas para la Epilepsia Farmacorresistente	Andres Kanner MD, FAAN
S34	Behavioral and Cognitive Neurology
S35	Child Neurology and Developmental Neurology II
S36	MS Therapeutics and Clinical Research
C244	Joint AAN and AHA/ASA Session: Bridging Racial and Ethnic Disparities in the Management of Stroke and Breakthroughs in Engaging Minority and Rural Communities in Stroke	Jose Romano MD, FAAN, Barbara Vickrey MD, MPH, FAAN
3:45 PM-4:30 PM
	Navigating Fellowship in Neurology	Ahmed Obeidat MD, PhD
4:00 PM-4:45 PM
	Diets and Supplements in MS: What's the Evidence Thus Far?	Vijayshree Yadav MD, FAAN
4:45 PM-5:15 PM
	Student Interest Group in Neurology (SIGN) Office Hours	Jennifer Bickel MD, FAAN
4:45 PM-5:30 PM
	A.B. Baker Lifetime Achievement in Neurologic Education Award Presentation: Top Ten Clinical, Educational, and Leadership Pearls	Steven Galetta MD, FAAN
5:15 PM-6:15 PM
	Neurology, Illustrated: The Neurology in Art	David Thaler MD, PhD

Thursday April 26, 2018
7:00 AM-9:00 AM
C179	Clinical EMG I: Principles and Practice of NCS and Needle EMG	Ruple Laughlin MD, FAAN
C172	Clinical Epilepsy I: Basics	Tracey Milligan MD, FAAN
C175	Clinical Pearls in Autoimmune Neurology: Real World Cases	Stacey Clardy MD, PhD
C176	The Dystonia: Diagnosis, Treatment and Update on Etiologies	Rachel Saunders-Pullman MD
C181	Preventive Neurology: How Neurologists Can Improve Outcomes That Matter to Patients	Joel Salinas MD
8:00 AM-9:00 AM
S38	"Best of" Session: Clinical Trial Updates in Neuromuscular Disorders
	Enhancing Epilepsy Care in Your Practice: In-Person Digital Learning and Emotional for Self-Management, Education, and Community Supports from the National Epilepsy Education and Awareness Collaborative	Barbara Jobst MD, FAAN, Patricia Shafer RN, MN
9:15 AM-11:30 AM
PL6	Controversies in Neurology Plenary Session
10:15 AM-10:45 AM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
11:30 AM-7:00 PM
P5	Poster Session V
11:45 AM-12:35 PM
PD5	MS and CNS Inflammatory Disease Poster Discussion Session
12:15 PM-12:45 PM
	FDA Introductory Seminar on Navigating the Regulatory Landscape for Neurological Devices and Moving Neurotechnologies to Patients and Caregivers	Katrina Gwinn MD, FAAN
12:30 PM-1:00 PM
	Office Hours: Making the Transition from Research Fellow to Clinical Research Faculty	Benzi Kluger MD, FAAN
12:45 PM-1:30 PM
	Effective Neurology Residency Program	Ralph Jozefowicz MD, FAAN
1:00 PM-1:30 PM
	Office Hours: Early Career Research Funding and Career Development	Ryan Walsh MD, PhD, FAAN
1:00 PM-1:45 PM
	Medical Marijuana: What do Neurologists Need to Know?	Jessica Robinson Papp MD, FAAN
1:00 PM-2:15 PM
S39	History of Neurology
1:00 PM-3:00 PM
N5	Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis	Eric Klawiter MD, FAAN, Ellen Mowry MD, FAAN
C193	Assessment of Rapidly Progressive Dementias I: Overview, Infections Presenting as Rapidly Progressive Dementia and Antibody-Mediated Rapidly Progressive Dementia	Michael Geschwind MD, PhD
C192	Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG	Mark Bromberg MD, PhD, FAAN
C182	Clinical Epilepsy II: Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly	Barbara Jobst MD, FAAN
C184	Behavioral Neurology I: Network Anatomy of Behavior and Language	Maria Gorno Tempini MD, PhD
C187	Cerebellar and Afferent Ataxias: Diagnosis and Management	Massimo Pandolfo MD, FAAN
C191	Neuro-otology I: The Common Peripheral Vestibular Disorders	Kevin Kerber MD
C195	Practical Training in Injection Techniques in the Treatment of Headache Disorders Skills Workshop (Registration Required)	Morris Levin MD, FAAN
C194	Actualización Sobre el Manejo del Ictus Cerebrovascular	Carlos Kase MD, FAAN, FAHA
S40	Acute Stroke Care
1:15 PM-1:45 PM
	Choosing a Career in Neuro-ophthalmology	Christopher Glisson DO, Marc Dinkin MD
2:00 PM-3:00 PM
	Using your Patients as Resources: Group Medical Visits for Improved Wellness and Efficiency	Mary Rensel MD, FAAN, Nancy Isenberg MD, MPH, FAAN
3:30 PM-4:00 PM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
3:30 PM-5:30 PM
C208	Assessment of Rapidly Progressive Dementias II: Neurodegenerative Diseases and Prion Diseases	Michael Geschwind MD, PhD
C206	Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches	Mark Bromberg MD, PhD, FAAN
C199	Neurology Update IV: Multiple Sclerosis, Neuro-ophthalmology, and Autoimmune Encephalopathies	Adam Quick MD
C197	Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG)	Tobias Loddenkemper MD
C198	Behavioral Neurology II: Memory and Attention	Maria Gorno Tempini MD, PhD
C203	Endovascular Treatment of Acute Stroke and Cerebrovascular Disease	Dileep Yavagal MD, FAAN
C205	Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness	Kevin Kerber MD
C209	Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop (Registration Required)	Allison Brashear MD, MBA, FAAN
S44	MS Risk Factors, Susceptibility, Diagnosis, and Cognitive Impairment
S45	Movement Disorders: Parkinsonian Disorders, Basic Science, and Imaging
S46	Advances in Spinal Muscular Atrophy
4:00 PM-4:45 PM
	Structural Acupuncture for Carpal Tunnel Syndrome	Alexandra Dimitrova MD
4:30 PM-5:00 PM
	Grantwriting 101: Getting Started	Logan Schneider MD
	Collaboration Corner: Career Opportunities in Emerging Neurologic Subspecialties	Ralph Jozefowicz MD, FAAN
4:30 PM-5:30 PM
	Neurology History: Weaving Past with Present	Christopher Goetz MD, FAAN
4:45 PM-5:30 PM
	Phonemic Verbal Fluency	Sanjida Chowdhury
6:30 PM-9:30 PM
C210	Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease	Anne Connolly MD, FAAN
C213	Case Studies: Unusual Movement Disorders	Kailash Bhatia MD, FAAN
C215	Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration	Daniel Kaufer MD, FAAN

Friday April 27, 2018
7:00 AM-9:00 AM
C219	The Early-Onset Dementias	Mario Mendez MD, PhD, FAAN
C217	Current Management of Incidental and Asymptomatic Cerebrovascular Lesions	Seemant Chaturvedi MD, FAAN, FAHA
C222	Therapy of Movement Disorders: A Case-based Approach	David Riley MD
C223	The Burden of Epilepsy: Managing Comorbidities and Quality of Life	Gregory Cascino MD, FAAN
8:00 AM-9:00 AM
S47	"Best of" Session: MS and CNS Inflammatory Diseases
8:00 AM-9:10 AM
	Role of Placebo in Neuromuscular Clinical Trials and in Management of NM Disorders	Aziz Shaibani MD, FAAN, Richard Barohn MD, FAAN
9:15 AM-11:30 AM
PL7	Neurology Year in Review: Emerging Therapies Plenary Session
10:15 AM-10:45 AM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
11:30 AM-5:30 PM
P6	Poster Session VI
11:45 AM-12:30 PM
	From Bench to Bedside to the International Landscape: How to Trail the Path to Project Your Work to the World	Fabricio De Oliveira MD, BBA, MSc, PhD
11:45 AM-12:35 PM
PD6	Movement Disorders Poster Discussion Session
12:00 PM-12:45 PM
	Outsmart Stress	Marie Pasinski MD
12:30 PM-1:00 PM
	Collaboration Corner: From Bench to Bedside to the International Landscape: How to Trail the Path to Project Your Work to the World	Fabricio De Oliveira MD, BBA, MSc, PhD
12:40 PM-1:10 PM
	How to Put Together an Effective Research Presentation	Enrique Leira MD, MS, FAAN
1:00 PM-3:00 PM
C224	Neuromyelitis Optica Spectrum Disorders	Dean Wingerchuk MD, FAAN
C225	Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia	Laura Tormoehlen MD
C229	Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders	Jill Ostrem MD
S48	Novel Biomarkers in Aging and Dementia
S51	Pediatric MS
1:00 PM-5:00 PM
C234	Epilepsy Skills Workshop: Focus on Treatment (Registration Required)	William Tatum DO, FAAN
1:30 PM-2:30 PM
	Live Intraoperative Monitoring	Constantine Moschonas MD, FAAN
2:40 PM-3:10 PM
	Recruiting Minorities	Bernadette Boden-Albala DrPH
3:00 PM-4:00 PM
	Ask Us Anything: Expert Panel on Stroke	Natalia Rost MD, MPH, FAAN, FAHA, Jose Biller MD, FAAN, FACP, FAHA, Italo Linfante MD
3:30 PM-4:00 PM
	Collaboration Corner: Wellness Break	Lucy Persaud Samaroo
3:30 PM-5:30 PM
C235	Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy	John Engstrom MD, FAAN
C236	Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission	Laura Tormoehlen MD
C238	Memory Disorders: A Case-based Approach	David Wolk MD
C241	Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders	Jill Ostrem MD
S52	MS and CNS Inflammatory Disease: Basic Science
S53	Epilepsy/Clinical Neurophysiology (EEG) III
S54	Ischemic Stroke Prevention
4:00 PM-4:30 PM
	Historical Perspective on Treating Epilepsy	Gregory Bergey MD, FAAN
4:30 PM-5:30 PM
	Ask the Expert: Discussion on Multiple Sclerosis	John Corboy MD, FAAN, Brian Weinshenker MD, FAAN, Barbara Giesser MD, FAAN

Universal Navigation

P2 - Poster Session II

Ready to register for the 2018 AAN Annual Meeting?

Related Courses

Footer